Targeted Treatment of Anerobic Cancer

ABSTRACT

The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor&#39;s metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy.

FIELD OF THE INVENTION

The present invention relates to a pharmaceutical cocktail and methodsof treatment involving said cocktail, in particular, a combination ofeffective amounts of a carbonic anhydrase inhibitor, in combination witheffective amounts of an angiogenesis inhibitor, including a vascularendothelial growth factor (VEGF) inhibitor such as bevacizumab for thetreatment of cancer. The merits of this invention are based on the factthat cancer in its untreated state uses both aerobic andanaerobic/glycolytic pathways and both must be treated if the bestresults are to be achieved. Treatment of both metabolic pathways morecompletely deprives cancer of ATP energy production, thereby producinggreater damage or killing of cancerous cells. Treatment of the aerobicpathway alone temporarily controls cancer but it induces mutation to aglycolytic form, which does not respond to anti-VEGF or otheranti-vascular growth factor agents.

In other embodiments, it relates to compositions and methods of treatingcancer involving effective amounts of a carbonic anhydrase inhibitor.Pharmaceutical compositions and methods of treating cancer (eliminatingthe tumor, shrinking the tumor, prolonging the life of the patient,increasing quality of life by decreasing the grade of adverse eventsseen with other cancer treatments, and/or preventing/reducing thelikelihood of the tumor's metastases) are additional aspects of thepresent invention. In addition, the present invention may be used tofavorably affect the therapeutic result of patients who have notresponded to alternative, traditional anti-cancer therapy.

BACKGROUND OF THE INVENTION

While a number of anti-angiogenesis agents have been reported, includingbevacizumab, it is not clear whether they possess the appropriatepharmacological effectiveness required to be therapeutically useful inthe treatment of cancer in many situations. Therefore, there is acontinued need for additional therapeutics to target such cancer andaugment or revive the effectiveness of anti-angiogenesis agents toprovide effective treatment of cancer.

SUMMARY OF THE INVENTION

The present invention relates to a pharmaceutical cocktail and methodsof treatment involving said cocktail, in particular, a combination ofeffective amounts of a carbonic anhydrase inhibitor, in combination witheffective amounts of an angiogenesis inhibitor, including a vascularendothelial growth factor (VEGF) inhibitor such as bevacizumab for thetreatment of cancer. In other embodiments, it relates to compositionsand methods of treating cancer involving effective amounts of a carbonicanhydrase inhibitor. Pharmaceutical compositions and methods of treatingcancer (eliminating the tumor, shrinking the tumor, prolonging the lifeof the patient, increasing quality of life by decreasing the grade ofadverse events seen with other cancer treatments, and/orpreventing/reducing the likelihood of the tumor's metastases) areadditional aspects of the present invention. In addition, the presentinvention may be used to favorably affect the therapeutic result ofpatients who have not responded to alternative, traditional anti-cancertherapy.

In one embodiment, the invention contemplates a method of treatingcancer comprising administering to a patient an effective amount of aloop diuretic and an angiogenesis inhibitor. In one embodiment, saidangiogenesis inhibitor is a humanized monoclonal antibody. In oneembodiment, said antibody is bevacizumab. In one embodiment, saidtreating comprises repeated administration of at least one of the loopdiuretic and angiogenesis inhibitor. In one embodiment, said loopdiuretic is bumetanide. In one embodiment, said cancer is hypoxiccancer. In one embodiment, said administering results in the shrinkageof said cancer. In one embodiment, said patient has metastases and saidadministration reduces metastases of said cancer.

In one embodiment, the invention contemplates a method of treatingcancer comprising administering to a patient an effective amount of acarbonic anhydrase inhibitor and an angiogenesis inhibitor. In oneembodiment, said angiogenesis inhibitor is a humanized monoclonalantibody. In one embodiment, said treating comprises repeatedadministration of at least one of the carbonic anhydrase inhibitor andangiogenesis inhibitor. In one embodiment, said antibody is bevacizumab.In one embodiment, said carbonic anhydrase inhibitor and an angiogenesisinhibitor are administered to said patient at the same time. In oneembodiment, said cancer is hypoxic cancer. In one embodiment, saidcarbonic anhydrase inhibitor is a carbonic anhydrase 9 and carbonicanhydrase 12 inhibitor. In one embodiment, said administering results inthe shrinkage of said cancer. In one embodiment, said patient hasmetastases and said administration reduces metastases of said cancer.

In one embodiment, the invention contemplates a pharmaceuticalcomposition comprising an effective amount of a loop diuretic and anangiogenesis inhibitor. In one embodiment, said angiogenesis inhibitoris bevacizumab. In one embodiment, said loop diuretic is bumetanide. Inone embodiment, the invention contemplates said pharmaceuticalcomposition formulated for oral administration. In one embodiment, theinvention contemplates said pharmaceutical composition formulated forparenteral administration. In one embodiment, the invention contemplatessaid pharmaceutical composition formulated for intravenousadministration.

In one embodiment, the invention contemplates a pharmaceuticalcomposition comprising an effective amount of a carbonic anhydraseinhibitor and an angiogenesis inhibitor. In one embodiment, saidangiogenesis inhibitor is bevacizumab. In one embodiment, said carbonicanhydrase inhibitor and said angiogenesis inhibitor are in a mixture. Inone embodiment, the invention contemplates said formulated for oraladministration. In one embodiment, the invention contemplates saidformulated for parenteral administration. In one embodiment, theinvention contemplates said formulated for intravenous administration.

In one embodiment, the invention contemplates a method for treating apatient with cancer, said method comprising: a) administering to saidpatient a carbonic anhydrase inhibitor, and b) occluding the bloodvessels providing blood to said cancer. In one embodiment, said canceris hypoxic cancer. In one embodiment, said treating results in theshrinkage of said cancer. In one embodiment, said occluding of bloodvessels providing blood to said cancer comprises embolization. In oneembodiment, said embolization comprises embolization with polymersembedded with carbonic anhydrase inhibitors. In one embodiment, saidoccluding of blood vessels providing blood to said cancer comprisesthermal ablation. In one embodiment, said treating of said cancer withthermal ablation is preceded with bumetanide treatment. In oneembodiment, said anhydrase inhibitor is bumetanide.

In one embodiment, the invention relates to a method of treating cancercomprising administering to a patient in need of therapy an effectiveamount of low dose, frequently administered combination of a carbonicanhydrase inhibitor and an angiogenesis inhibitor. In one embodiment,said angiogenesis inhibitor is selected from the group consisting ofZD6474, ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab, mv833,anti-FLT-1 ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248,and mixtures thereof. In one embodiment, said angiogenesis inhibitor isbevacizumab. In one embodiment, said carbonic anhydrase inhibitor isbumetanide. In one embodiment, said carbonic anhydrase inhibitor is acarbonic anhydrase 9 and carbonic anhydrase 12 inhibitor. In oneembodiment, the treatment results in one or more of clinical benefitremission, an increased quality of life or prolongation of survival ofthe patient. In one embodiment, said treatment results in the shrinkageof a tumor or prolonged stability of the cancer. In one embodiment, saidtreatment reduces metastases of said cancer.

In one embodiment, the invention relates to a pharmaceutical compositioncomprising an effective amount of a combination of a carbonic anhydraseinhibitor and an angiogenesis inhibitor. In one embodiment, saidangiogenesis inhibitor is selected from the group consisting of ZD6474,ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab, mv833, anti-FLT-1ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248, andmixtures thereof. In one embodiment, said angiogenesis inhibitor isbevacizumab. In one embodiment, said carbonic anhydrase inhibitor isbumetanide. In one embodiment the invention relates to the compositiondescribed above adapted for oral administration. In one embodiment theinvention relates to the composition described above adapted forparenteral administration. In one embodiment the invention relates tothe composition described above adapted for intravenous administration.

In one embodiment, the invention relates to a method for treating apatient with cancer, wherein said cancer is unresponsive to traditionaltherapy, said method comprising administering to said patient acombination of a carbonic anhydrase inhibitor and an angiogenesisinhibitor in amounts effective to provide a clinical benefit remission,an increased quality of life or prolongation of survival of the patient.In one embodiment, said treatment results in the shrinkage of a tumor orprolonged stability of the cancer. In one embodiment, said methodresults in a complete remission of said cancer. In one embodiment, saidangiogenesis inhibitor is bevacizumab. In one embodiment, said carbonicanhydrase inhibitor is bumetanide.

In one embodiment, the invention relates to the treatment of hypoxiccancer. In one embodiment, treatment of hypoxic cancer includes targetedbloodstream injection of a carbonic anhydrase inhibitor, such asbumetanide. In one embodiment, treatment comprises catheterization ofthe hepatic artery. In one embodiment, treatment comprises occludingarteries with the treatment of bumetanide. In one embodiment, treatmentcomprises embolization. In one embodiment, treatment comprisesembolization with polymers embedded with carbonic anhydrase inhibitors.In one embodiment, said carbonic anhydrase inhibitors include a carbonicanhydrase 9 or 12 inhibitor, such as bumetanide. In one embodiment, saidpolymers embedded with carbonic anhydrase inhibitors slowly releasebumetanide. In one embodiment, said treatment bumetanide is givenintravenously in combination with artery embolization with polymersembedded with carbonic anhydrase inhibitors.

In one embodiment, the invention contemplates the treatment of cancer.In one embodiment, said cancer comprises well-defined tumors. In oneembodiment, said treatment involves thermal ablation of arteriessupplying blood to well defined tumors in combination with treatmentwith bumetanide. In one embodiment, treatment comprises additionaltreatment with an angiogenesis inhibitor. In one embodiment, saidangiogenesis inhibitor is selected from the group consisting of ZD6474,ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab, mv833, anti-FLT-1ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248, andmixtures thereof.

In one embodiment, the invention contemplates a method for treating apatient with cancer, said method comprising administering to saidpatient a carbonic anhydrase inhibitor and occlusion of blood vesselsproviding blood to said cancer effective to provide a clinical benefitremission, an increased quality of life or prolongation of survival ofthe patient. In one embodiment, said cancer is hypoxic cancer. In oneembodiment, said treatment results in the shrinkage of a tumor orprolonged stability of the cancer. In one embodiment, said methodresults in a complete remission of said cancer. In one embodiment, saidocclusion of blood vessels providing blood to said cancer comprisesembolization. In one embodiment, said embolization comprisesembolization with polymers embedded with carbonic anhydrase inhibitors.This embodiment provides treatment of aerobic cancer cells by occlusionof the arteries and treatment of the glycolytic cancer cells by directaction of the carbonic anhydrase inhibitor and indirectly by inhibitionof glycolysis by the induced low pH. In one embodiment, said carbonicanhydrase inhibitor is bumetanide. In one embodiment, said occlusion ofblood vessels providing blood to said cancer comprises thermal ablation.In one embodiment, said treatment of said cancer with thermal ablationis preceded with bumetanide treatment.

The described features, structures, or characteristics of the inventionmay be combined in any suitable manner in one or more embodiments. Inthe following description, numerous specific details are recited toprovide a thorough understanding of embodiments of the invention. Oneskilled in the relevant art will recognize, however, that the inventionmay be practiced without one or more of the specific details, or withother methods, components, materials, and so forth. In other instances,well-known structures, materials, or operations are not shown ordescribed in detail to avoid obscuring aspects of the invention.

DEFINITIONS

To facilitate the understanding of this invention, a number of terms aredefined below. Terms defined herein have meanings as commonly understoodby a person of ordinary skill in the areas relevant to the presentinvention. Terms such as “a”, “an” and “the” are not intended to referto only a singular entity, but include the general class of which aspecific example may be used for illustration. The terminology herein isused to describe specific embodiments of the invention, but their usagedoes not delimit the invention, except as outlined in the claims.

The term “patient” or “subject” is used throughout the specification todescribe an animal, generally a mammal and preferably a human, to whomtreatment, including prophylactic treatment, with the compositionsaccording to the present invention is provided. For treatment of thoseinfections, conditions or disease states, which are specific for aspecific animal such as a human patient, the term patient refers to thatspecific animal.

The term “neoplasia” or “cancer” is used throughout the specification torefer to the pathological process that results in the formation andgrowth of a cancerous or malignant neoplasm, i.e., abnormal tissue thatgrows by cellular proliferation, often more rapidly than normal andcontinues to grow after the stimuli that initiated the new growth cease.Malignant neoplasms show partial or complete lack of structuralorganization and functional coordination with the normal tissue and mostinvade surrounding tissues, metastasize to several sites, and are likelyto recur after attempted removal and to cause the death of the patientunless adequately treated. As used herein, the term neoplasia is used todescribe all cancerous disease states and embraces or encompasses thepathological process associated with malignant hematogenous, ascitic andsolid tumors. Representative cancers include, for example, stomach,colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpusuteri, ovary, prostate, testis, bladder, renal, brain/CNS, head andneck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiplemyeloma, leukemia, melanoma, acute lymphocytic leukemia, acutemyelogenous leukemia, Ewing's sarcoma, small cell lung cancer,choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairycell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer andlymphoma, among others, including soft tissue sarcomas, which may betreated by the combination of compounds according to the presentinvention.

The term “remission” or “clinical benefit remission” is used to describea remission in a patient's cancer, which may be a complete remission, apartial remission or evidence of stability of the disease.

The term “coadministration” or “combination therapy” is used to describea therapy in which at least two active compounds or compositions ineffective amounts (in the present application, at least bumetanide iscoadministered with the angiogenesis inhibitor, preferably bevacizumabalso being coadministered or being administered before or after theadministration of bumetanide) to treat cancer, and preferably bothcompounds are used to treat a disease state or condition as otherwisedescribed herein at the same time. In some embodiments, the inventioninvolves administration of an additional chemotherapy compound(s) orcomposition(s).

Although the term coadministration preferably includes theadministration of at least two active compounds to the patient at thesame time, it is not necessary that the compounds be administered to thepatient at the same time, although effective amounts of the individualcompounds will be present in the patient at the same time.

The term “traditional cancer therapy” as used herein includes, but isnot limited to radiation, surgical removal of cancerous tissue, andtreatment with chemotherapeutic drugs, which generally have significanttoxicity and undesirable side effects.

The term “carbonic anhydrase(s)” (CAs) as used herein refer to a largefamily of zinc metalloenzymes that catalyze the reversible hydration ofcarbon dioxide. They participate in a variety of biological processes,including, but not limited to, respiration, calcification, acid-basebalance, bone resorption, and the formation of aqueous humor,cerebrospinal fluid, saliva, and gastric acid. Carbonic anhydrase 9(CA9) is an enzyme that in humans is encoded by the CA9 gene andcarbonic anhydrase 12 (CA12) is an enzyme that in humans is encoded bythe CA12 gene. CA9 and CA12 are most commonly present in many cancertypes, i.e. colon, breast, brain, kidney, lung etc. but uncommonlypresent in normal tissues, making them suitable for therapeutictargeting.

The term “angiogenesis inhibitor”, “vascular endothelial growth factorinhibitor” “VEGF inhibitor” or “anti-VEGF therapy” all used withincontext, refers to a compound, composition or therapy which inhibits orotherwise prevents the angiogenesis effects of vascular endothelialgrowth factor (VEGF, a factor which is involved in the angiogenesis oftissue, including growth in and vascularization of tumors), regardlessof mechanism.

As used herein, bumetanide (also known under trade names Bumex orBurinex) is a loop diuretic, a carbonic anhydrase inhibitor, and anaquaporin inhibitor. Bumetanide is a thiazide diuretic. The IUPAC nameis 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid. Bumetanide has thechemical structure:

As used herein, thiazides are a class of drug that promotes water lossfrom the body ((diuretics)). They inhibit Na+/Cl— reabsorption from thedistal convoluted tubules in the kidneys. Thiazides also cause loss ofpotassium and an increase in serum uric acid. The chemical structure ofthe original thiazide diuretics contained a thiazide ring system; theterm is also used for drugs with a similar action that are notchemically thiazides, such as chorthalidone.

As used herein, aquaporins refer to proteins embedded in the cellmembrane that regulate the flow of water. Aquaporins selectively conductwater molecules in and out of the cell, while preventing the passage ofions and other solutes. Also known as water channels, aquaporins areintegral membrane pore proteins. Some of them, known asaquaglyceroporins, transport also other small uncharged solutes, such asglycerol, carbon dioxide, ammonia and urea across the membrane,depending on the size of the pore.

As used herein, embolization is a non-surgical, minimally invasiveprocedure performed by an interventional radiologist and interventionalneuroradiologists. It involves the selective occlusion of blood vesselsby purposely introducing emboli. The purpose of embolization is toprevent blood flow to an area of the body, which effectively can shrinka tumor or block an aneurysm and/or deliver therapeutic drugs or/andagents. The procedure is carried out as an endovascular procedure by aconsultant radiologist in an interventional suite. It is common for mostpatients to have the treatment carried out with little or no sedation,although this depends largely on the organ to be embolized. Patients whoundergo cerebral embolization or portal vein embolization are usuallygiven a general anesthetic. Access to the organ in question is acquiredby means of a guidewire and catheter(s). Depending on the organ, thiscan be very difficult and time consuming. The position of the correctartery or vein supplying the pathology in question is located by digitalsubtraction angiography (DSA). These images are then used as a map forthe radiologist to gain access to the correct vessel by selecting anappropriate catheter and or wire, depending on the ‘shape’ of thesurrounding anatomy. Once in place, the treatment can begin. Theartificial embolus used is usually, but not limited to, one of thefollowing: Guglielmi detachable coil or hydrocoil, particles, foam, andplug.

As used herein, thermal ablation is a method of removing aberrant tissuefrom within the body preferably via minimally invasive procedures. Thereare several types of thermal ablation used to destroy targeted tissue:cryoablation uses extremely cold temperatures to freeze diseased tissue,radiofrequency ablation uses heat generated by radiofrequency energy,microwave ablation uses heat generated by microwave energy, Laserablation uses heat from a laser beam, and ultrasound ablation uses heatfrom focused ultrasound energy.

As used herein, the “nano knife system” is a minimally invasive cancertreatment that uses irreversible electroportation technology toprecisely target and kill hard-to-reach tumors at the cellular level. Itemploys irreversible electroporation that uses a series of microsecondelectrical pulses.

The term “occluding” as used herein refers to cause to become closed,such as blood vessels; to obstruct or occlude an artery. Embolization isone method of occluding blood vessels or lymphatic vessels.

The term “salts”, as used herein, refers to any salt that complexes withidentified compounds contained herein while retaining a desiredfunction, e.g., biological activity. Examples of such salts include, butare not limited to, acid addition salts formed with inorganic acids(e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoricacid, nitric acid, and the like), and salts formed with organic acidssuch as, but not limited to, acetic acid, oxalic acid, tartaric acid,succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid,benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic,acid, naphthalene sulfonic acid, naphthalene disulfonic acid, andpolygalacturonic acid. Pharmaceutically acceptable salts also includebase addition salts, which may be formed when acidic protons present arecapable of reacting with inorganic or organic bases. Suitablepharmaceutically-acceptable base addition salts include metallic salts,such as salts made from aluminum, calcium, lithium, magnesium,potassium, sodium and zinc, or salts made from organic bases includingprimary, secondary and tertiary amines, substituted amines includingcyclic amines, such as caffeine, arginine, diethylamine, N-ethylpiperidine, histidine, glucamine, isopropylamine, lysine, morpholine,N-ethyl morpholine, piperazine, piperidine, triethylamine, andtrimethylamine. All of these salts may be prepared by conventional meansfrom the corresponding compound of the invention by reacting, forexample, the appropriate acid or base with the compound of theinvention. Unless otherwise specifically stated, the present inventioncontemplates pharmaceutically acceptable salts of the consideredpro-drugs.

In addition, atoms making up the compounds of the present invention areintended to include all isotopic forms of such atoms. Isotopes, as usedherein, include those atoms having the same atomic number but differentmass numbers. By way of general example and without limitation, isotopesof hydrogen include tritium and deuterium, and isotopes of carboninclude ¹³C and ¹⁴C. Similarly, it is contemplated that one or morecarbon atom(s) of a compound of the present invention may be replaced bya silicon atom(s). Furthermore, it is contemplated that one or moreoxygen atom(s) of a compound of the present invention may be replaced bya sulfur or selenium atom(s).

In structures wherein stereochemistry is not explicitly indicated, it isassumed that all stereochemistry is considered and all isomers claimed.

Any undefined valency on an atom of a structure shown in thisapplication implicitly represents a hydrogen atom bonded to the atom.Bonds to copper (Cu) metal may be coordinate bonds and are notnecessarily considered covalent.

The term “effective,” as that term is used in the specification and/orclaims, means adequate to accomplish a desired, or hoped for result.

The term “hydrate” when used as a modifier to a compound means that thecompound has less than one (e.g., hemihydrate), one (e.g., monohydrate),or more than one (e.g., dihydrate) water molecules associated with eachcompound molecule, such as in solid forms of the compound.

An “isomer” of a first compound is a separate compound in which eachmolecule contains the same constituent atoms as the first compound, butwhere the configuration of those atoms in three dimensions differs.

As used herein, the term “patient” or “subject” refers to a livingmammalian organism, such as a human, monkey, cow, sheep, goat, dog, cat,mouse, rat, guinea pig, or transgenic species thereof. In certainembodiments, the patient or subject is a primate. Non-limiting examplesof human subjects are adults, juveniles, infants and fetuses.

The term “Pharmaceutically acceptable” means that which is useful inpreparing a pharmaceutical composition that is generally safe, non-toxicand neither biologically nor otherwise undesirable and includes thatwhich is acceptable for veterinary use as well as human pharmaceuticaluse.

“Pharmaceutically acceptable salts” means salts of compounds of thepresent invention which are pharmaceutically acceptable, as definedabove, and which possess the desired pharmacological activity. Suchsalts include acid addition salts formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like; or with organic acids such as1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,2-naphthalenesulfonic acid, 3-phenylpropionic acid,4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid),4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, acetic acid,aliphatic mono- and dicarboxylicacids, aliphatic sulfuric acids,aromatic sulfuric acids, benzenesulfonic acid, benzoic acid,camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid,cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid,glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid,heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid,laurylsulfuric acid, maleic acid, malic acid, malonic acid, mandelicacid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoicacid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substitutedalkanoic acids, propionic acid, p-toluenesulfonic acid, pyruvic acid,salicylic acid, stearic acid, succinic acid, tartaric acid,tertiarybutylacetic acid, trimethylacetic acid, and the like.Pharmaceutically acceptable salts also include base addition salts,which may be formed when acidic protons present are capable of reactingwith inorganic or organic bases. Acceptable inorganic bases includesodium hydroxide, sodium carbonate, potassium hydroxide, aluminumhydroxide and calcium hydroxide. Acceptable organic bases includeethanolamine, diethanolamine, triethanolamine, tromethamine,N-methylglucamine and the like. It should be recognized that theparticular anion or cation forming a part of any salt of this inventionis not critical, so long as the salt, as a whole, is pharmacologicallyacceptable. Additional examples of pharmaceutically acceptable salts andtheir methods of preparation and use are presented in Handbook ofPharmaceutical Salts: Properties, and Use (P. H. Stahl & C. G. Wermutheds., Verlag Helvetica Chimica Acta, 2002) [1] herein incorporated byreference. Unless otherwise specifically stated, the present inventioncontemplates pharmaceutically acceptable salts of the consideredpro-drugs.

As used herein, “predominantly one enantiomer” means that a compoundcontains at least about 85% of one enantiomer, or more preferably atleast about 90% of one enantiomer, or even more preferably at leastabout 95% of one enantiomer, or most preferably at least about 99% ofone enantiomer. Similarly, the phrase “substantially free from otheroptical isomers” means that the composition contains at most about 15%of another enantiomer or diastereomer, more preferably at most about 10%of another enantiomer or diastereomer, even more preferably at mostabout 5% of another enantiomer or diastereomer, and most preferably atmost about 1% of another enantiomer or diastereomer.

The term “Prevention” or “preventing” as used herein includes: (1)inhibiting the onset of a disease in a subject or patient which may beat risk and/or predisposed to the disease but does not yet experience ordisplay any or all of the pathology or symptomatology of the disease,and/or (2) slowing the onset of the pathology or symptomatology of adisease in a subject or patient which may be at risk and/or predisposedto the disease but does not yet experience or display any or all of thepathology or symptomatology of the disease.

The terms “reduce,” “inhibit,” “diminish,” “suppress,” “decrease,”“prevent” and grammatical equivalents (including “lower,” “smaller,”etc.) when in reference to the expression of any symptom in an untreatedsubject relative to a treated subject, mean that the quantity and/ormagnitude of the symptoms in the treated subject is lower than in theuntreated subject by any amount that is recognized as clinicallyrelevant by any medically trained personnel. In one embodiment, thequantity and/or magnitude of the symptoms in the treated subject is atleast 10% lower than, at least 25% lower than, at least 50% lower than,at least 75% lower than, and/or at least 90% lower than the quantityand/or magnitude of the symptoms in the untreated subject.

The term “saturated” when referring to an atom means that the atom isconnected to other atoms only by means of single bonds.

A “stereoisomer” or “optical isomer” is an isomer of a given compound inwhich the same atoms are bonded to the same other atoms, but where theconfiguration of those atoms in three dimensions differs. “Enantiomers”are stereoisomers of a given compound that are mirror images of eachother, like left and right hands. “Diastereomers” are stereoisomers of agiven compound that are not enantiomers.

Enantiomers are compounds that individually have properties said to have“optical activity” and consist of molecules with at least one chiralcenter, almost always a carbon atom. If a particular compound isdextrorotary, its enantiomer will be levorotary, and vice-versa. Infact, the enantiomers will rotate polarized light the same number ofdegrees, but in opposite directions. “Dextrorotation” and “levorotation”(also spelled laevorotation) refer, respectively, to the properties ofrotating plane polarized light clockwise (for dextrorotation) orcounterclockwise (for levorotation). A compound with dextrorotation iscalled “dextrorotary,” while a compound with levorotation is called“levorotary.”

A standard measure of the degree to which a compound is dextrorotary orlevorotary is the quantity called the “specific rotation” “[α]”.Dextrorotary compounds have a positive specific rotation, whilelevorotary compounds have negative. Two enantiomers have equal andopposite specific rotations. A daxtrorotary compound is prefixed “(+)-”or “d-”. Likewise, a levorotary compound is often prefixed “(−)-” or“l-”. These “d-” and “l-” prefixes should not be confused with the “D-”and “L-” prefixes based on the actual configuration of each enantiomer,with the version synthesized from naturally occurring (+)-compound beingconsidered the D-form. A mixture of enantiomers of the compounds isprefixed “(±)-”. An equal mixture of enantiomers of the compounds isconsidered “optically inactive.”

The invention contemplates that for any stereocenter or axis ofchirality for which stereochemistry has not been defined, thatstereocenter or axis of chirality can be present in its R form, S form,or as a mixture of the R and S forms, including racemic and non-racemicmixtures.

The present invention contemplates the above-described compositions in“therapeutically effective amounts” or “pharmaceutically effectiveamounts”, which means that amount which, when administered to a subjector patient for treating a disease, is sufficient to effect suchtreatment for the disease or to ameliorate one or more symptoms of adisease or condition (e.g. ameliorate pain).

As used herein, the terms “treat” and “treating” are not limited to thecase where the subject (e.g. patient) is cured and the disease iseradicated. Rather, the present invention also contemplates treatmentthat merely reduces symptoms, improves (to some degree) and/or delaysdisease progression. It is not intended that the present invention belimited to instances wherein a disease or affliction is cured. It issufficient that symptoms are reduced.

“Subject” refers to any mammal, preferably a human patient, livestock,or domestic pet.

In a specific embodiment, the term “pharmaceutically acceptable” meansapproved by a regulatory agency of the federal or a state government orlisted in the U.S. Pharmacopeia or other generally recognizedpharmacopeia for use in animals, and more particularly in humans. Theterm “carrier” refers to a diluent, adjuvant, excipient or vehicle withwhich the active compound is administered. Such pharmaceutical vehiclescan be liquids, such as water and oils, including those of petroleum,animal, vegetable or synthetic origin, such as peanut oil, soybean oil,mineral oil, sesame oil and the like. The pharmaceutical vehicles can besaline, gum acacia, gelatin, starch paste, talc, keratin, colloidalsilica, urea, and the like. In addition, auxiliary, stabilizing,thickening, lubricating and coloring agents can be used. Whenadministered to a subject, the pharmaceutically acceptable vehicles arepreferably sterile. Water can be the vehicle when the active compound isadministered intravenously. Saline solutions and aqueous dextrose andglycerol solutions can also be employed as liquid vehicles, particularlyfor injectable solutions. Suitable pharmaceutical vehicles also includeexcipients such as starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene glycol,water, ethanol and the like. The present compositions, if desired, canalso contain minor amounts of wetting or emulsifying agents, or pHbuffering agents.

Pharmaceutically acceptable sugars include but are not limited tosucrose, dextrose, maltose, galactose, rhamnose, and lactose.Pharmaceutically acceptable sugar alcohols include but are not limitedto mannitol, xylitol, and sorbitol.

As used herein, “extended release” refers to providing continuoustherapeutic level of an active agent (e.g., neuregulin) over a period oftime. The extended release includes, without limitation various forms ofrelease, such as continuous release, controlled release, delayedrelease, depot, gradual release, long-term release, programmed release,prolonged release, proportionate release, protracted release,repository, retard, slow release, spaced release, sustained release,time coat, timed release, delayed action, extended action, layered-timeaction, long acting, prolonged action, repeated action, slow acting,sustained action, sustained-action medications, and controlled release.The ability to obtain extended release, controlled release, timedrelease, sustained release, delayed release, long acting, pulsatiledelivery or immediate release is performed using well-known proceduresand techniques available to the ordinarily skilled artisan.

The amount of time over which the active agent continues to be releaseddepends on the characteristics of the active agent and the extendedrelease technology or technologies used, but in all cases is longer thanthat of administration of the active agent without the extended releasetechnology or technologies. Other forms of slow release compositions aredescribed in the following: U.S. Pat. No. 4,828,836 [2], U.S. Pat. No.6,190,591 [3].

DESCRIPTION OF THE FIGURES

The accompanying figures, which are incorporated into and form a part ofthe specification, illustrate several embodiments of the presentinvention and, together with the description, serve to explain theprinciples of the invention. The figures are only for the purpose ofillustrating a preferred embodiment of the invention and are not to beconstrued as limiting the invention.

FIG. 1A-1B shows a multidetector computed tomography (MDCT) of theabdomen performed on a patient with severe abdominal pain.

FIG. 2A-2B shows blood volume calculated using the area under thecontrast curve over time (AUC).

FIG. 3 shows a scatter plot of relative cerebral blood volume (rCBV)ratios for each tumor shows significant difference between the low-gradeand high-grade oligodendroglial tumors (p<0.05)

FIG. 4A-4B shows scans of a 44-year-old man with low-gradeoligoastrocytoma. FIG. 4A shows a T2-weighted image. FIG. 4B shows arelative cerebral blood volume map shows low tumoral vascularity.

FIG. 5A-5B shows scans of a 64-year-old man with anaplasticoligodendroglioma. FLAIR image corresponding to FIG. 5A shows a rightfrontal cortex-based mass (arrow). FIG. 5B shows a relative cerebralblood volume map shows elevated tumor vascularization of tumor.

FIG. 6 shows that benign lesions typically have a kinetic curve whichshows an increase or plateau flow, Ia and Ib. Cancer shows a decreasing“washout” type II and type III.

FIG. 7A and FIG. 7B show a region of interest (black oval on the leftimage) and corresponding time signal curve of an enhancing mass in theright breast, with an irregular shape, speculated borders, heterogeneousinternal enhancement, and first initial enhancement followed by earlywashout.

FIG. 8A-8B shows a Myxoid fibroadenoma. FIG. 8A shows the region ofinterest (black oval on the left image) and FIG. 8B shows thecorresponding time-signal intensity curve.

FIG. 9 shows a graph with three curves measured at different sites inthe same breast cancer.

FIG. 10 shows changes in kinetic curves are also useful for assessingtreatment response, as they show the early changes in the washout curve.

FIG. 11 shows MR imaging of breats and show the graphs illustrating theabsolute decreases in K^(trans) from the baseline to cycles 1 and 4.

FIG. 12A-12C shows a gadolinium-enhanced MRI of liver metastases showingwashout characteristic of malignancy.

FIG. 13A shows characteristic growth curve of an iris implant (BP No.29R) plotted on a semi-logarithmic scale. FIG. 13B. Diagram shows anoverlay over the original Gimbrone diagram illustrating the ALPHAconcept.

FIG. 14 shows FDG PET scan of metastatic colon cancer in the liver.

FIG. 15 shows substrate and metabolic profiles found in premalignantintraductal tumor using reaction-diffusion modeling.

FIG. 16 shows a map of peritumoral H⁺ flow using vectors generated fromthe pH_(e) distribution around PC3N/Efgp.

FIG. 17A-17B shows hyaluronan attaches to the cell membrane receptor,RHAMM, thus permitting transcription of motogenic genes.

FIG. 18 show a CT scan showing a mass in the medial side of the breast,horizontal arrow as well as early metastases to small axillary node,vertical arrow.

FIG. 19A-19D shows arterial and venous EC have molecularly definedidentities that are evident before circulatory flow or eventubulogenesis.

FIG. 20A-20E shows ear lymphatics after intravital infusion of colloidalcarbon in a control mouse and in mice injected at the indicatedintervals with Ad-PlGF or Ad-VEGF-A164.

FIG. 21 shows angiogenic response to Ad-VEGF-A164 in the ears of nudemice at the indicated times and magnifications

FIG. 22A-22C show vessels in ear skin at 18 hours after local injectionof adeno-vpf/vegf

FIG. 23 shows a schematic diagram of mother vessel formation andevolution into daughter capillaries, vascular malformations andglomeruloid bodies.

FIG. 24A-24I shows FGF-2 stimulates corneal lymphangiogenesis.

FIG. 25 shows an overview of the dilated main ovarian vein located closeto the tumor margin (at the right) and near the ovarian artery (at theleft).

FIG. 26 show the rate of lymphatic endothelial cell proliferation isgreater than that of vascular endothelial cells during the transitioninto the malignant form (SCC-I-P, SCC-I-C, SCC-II-P).

FIG. 27 shows the growth of a tumor from single 4T1 cells in a BALB/cmouse window chamber.

FIG. 28 shows a summary of the microenvironment.

FIG. 29A-29B shows graphs demonstrating the effects of bFGF and VEGF onMOLT-3 tumor growth.

FIG. 30A-30I shows suppression of hypoxic response by selectivelykilling hypoxic cells does not delay incipient tumor angiogenesis.

DETAILED DESCRIPTION OF THE INVENTION I. Introduction

The currently accepted oxygen based arteriogenesis concept evolved froman experiment by Gimbrone [4] and Folkman [5] (both herein incorporatedby reference) which reported the interruption of tumor dormancy byvasculogenesis. Although no oxygen measurements were made, it has sincebeen inferred that hypoxia induces the VEGF (vascular endothelial growthfactor) which initiates arterial growth.

Of the voluminous amounts of research data on angiogenesis, numerousdata has been contradictory and inconsistent with the currenthypoxia/arterial based theory, Sheikh, A. Y. et al. (2000) [6] hereinincorporated by reference. Hypoxia is not necessary for angiogenesisbecause it occurs in normoxic wounds. Relative to treatment, it had beenbelieved that anti-VEGF drugs would destroy arteries and cancer butrecently the FDA withdrew its approval of the use of Avastin as aprimary treatment for breast cancer (Stein 2011) [7], incorporatedherein by reference. This negative action was based on lack ofeffectiveness and increased incidence of complications with Avastin,most notably venous thrombophlebitis [8-11], incorporated herein byreference. Another contradictory observation regarding anti-VEGF drugsare that they transiently increase arterial flow (or normalize) ratherthan decreasing it [12-15], incorporated herein by reference.

Other important inconsistencies are based on imaging studies of tumorperfusion. Vascular physiology dictates that arterial flow cannot occurwithout pre-existing venous outflow, (FIG. 1A-1B); ingrowth of arterieswithout veins cannot occur. Perfusion studies using MRI (magneticresonance imaging), MDCT (multidetector computed tomography), andultrasound show that the most reliable vascular parameters are venousnot arterial.

In an attempt to resolve these inconsistencies, data was studied fromdiverse fields (i.e. bioenergetics, biomechanics, genetics, biomarkers,cytoarchitecture, proteonics, and signaling pathways) related toangiogenesis and found that much of the reported data can be interpretedto suggest an alternate angiogenesis theory. By collating these data,the following concept was formulated: Cancers prefer glycolyticmetabolism, requiring only glucose and not oxygen, which makes ample ATPenergy but also creates large amounts of lactate and low pH. Dependingupon the concentration levels these waste products may provide specificbenefits to cancer, cause tumor dormancy, and transform themicroenvironment. Angiogenesis follows transformation and interruptstumor dormancy, thus promoting cancer growth. The vascular changes occursequentially in the lymphatics, veins, and lastly, the arteries (notfirst, as previously believed).

We propose the newly formulated concept, designated by the acronymA³L2PHA (Aerobic Anaerobic Acid and Lactate sequentially inducedLymphatics, PHlebos/veins Arteries) for consideration by the scientificcommunity.

II. Contradictions and Inconsistencies of the Current Theory

The impetus for this new angiogenesis concept has been the revelation ofnumerous inconsistencies and paradoxes. Some will only be mentioned andothers discussed more fully to emphasize the need for a new paradigm.From the basic science arena, it has been noted that anti-VEGF drugs donot decrease central arterial blood flow but actually increases it, in aprocess called “normalization” [12-15]. Interruption of the arterialsupply to a tumor by surgical ligature or angiographic bland (nochemical agents) embolization has little long-term effect on tumorviability. Although cancer becomes hypovascular as they enlarge, theiraggressive nature increases when hypoxia is present.

There are two inconsistencies that will be more fully discussed: 1) thelack of effectiveness of anti-VEGF drugs for the primary treatment oftumors; and 2) the inconsistencies noted in perfusion imaging of cancerin clinical patients.

FDA Withdew its Approval of an Anti-VEGF Drug

In July 2010, the Oncologic Drug Advisory Committee withdrew itsapproval of Avastin for the treatment of breast cancer. This action wastaken because of its lack of effectiveness and its association withhigher complications Nalluri, S. R. et al. (2008) [11], incorporatedherein by reference.

Angiographic Principles and Modern Perfusion Studies Demonstrate theImportance of the Venous System for Cancer

Considering the numerous and varying reports, greater significance mustbe given to patient studies reflecting clinical reality. In the clinicalimaging realm, experience based on angiography and the vascularperfusion of tumors, the importance of the venous system is quiteevident.

The concept that arteries form first is contrary to basic vascularphysiology because without venous outflow arterial inflow cannot occuror be sustained. This is unequivocally well known to angiographers andsurgeons as surgical repair of an occluded vascular stenosis cannotsucceed unless there is adequate downstream flow. Most intestinalinfarctions treated by abdominal surgeons are caused by venous occlusionwhich impair arterial flow and causes infarction.

Using modern multiphasic contrast enhanced CTA (computed tomographicarteriography) and CTV (computed tomographic venography), withreconstructions, such venous infarctions can now be imaged, (FIG.1A-1B).

FIG. 1A-1B shows a multidetector computed tomography (MDCT) of theabdomen performed on a patient with severe abdominal pain, multiplanarreconstructions were obtained. Arteries and veins are displayed. FIG.1A: The coronal plane shows the inferior mesenteric vein with contrastflow noted in the lateral branch, indicated by the vertical arrow, butwith no flow in the main vein, as indicated by the horizontal veins.Note the edema and stranding for the splenic flexture, which isinfracted because there is no arterial flow. Extensive edema of thesplenic flexure region is also noted. FIG. 1B: Combined Arterial andvenous enhancement shows collateral veins draining the descending colon,but not the splenic flexure (SF). Arterial flow is maintained to thedescending colon but there is no arterial supply to splenic flexure.

Additional data on cancer perfusion obtained from MRI, MDCT andultrasound reveal that the most consistently useful assessments of tumorvascular perfusion are derived from the venous and not the arterialsystem. The specific assessment techniques will only be discussed onlyin general terms, although all of the modern methods, such as DCE MRI,MDCT, and ultrasound use similar techniques. With each modality,baseline unenhanced images are obtained and subsequent repetitive imagesare obtained at varying time intervals during an intravenous bolusinjection of appropriate contrast material (i.e. gadolinium, iodinated,or microbubbles)

The contrast-enhanced images can be analyzed visually or more vigorouslyby graphing or analyzed mathematically. Such contrast time curves are anessential component of MRI vascular imaging. The typical graph shows thedensity or intensity curve over the time intervals, (FIG. 2a ).Depending upon the character of the arteries, veins, and artcriovenousshunts the shape of the curve varies (FIG. 2b ). With MRI,semiquantitative measurements are made because absolute values ofintensity, density, or flow measurements are quite variable due to thetechnical, paramagnetic, physiologic and equipment factors. Mathematicalcalculation of the permeability expressed as K or K, can be calculatedWorkman, P. et al. (2006) [16] and Miller, J. et al. (2005) [17],incorporated herein by reference.

FIG. 2a . shows data obtained from a contrast enhanced study graph isused to construct an intensity/time or density/time curve. The diagramcompares the contrast time curve for the aorta (A) and a typical densitytime curve over a mass. The AUC (area under the curve) represents theopacified blood as seen during the arterial and venous outflow phase.The shape of the curve can be visually analyzed as a “kinetic curve”, asis commonly done with gadolinium enhanced DCE MRI mammography. Althoughinflow and outflow are related, the outflow curve mostly depends uponthe venous characteristics. The second image in FIG. 2b shows, a “spike”which requires rapid inflow and rapid outflow. In either curve, theoutflow down slope depends on the venous system.

FIG. 2b shows a demonstration of the CBV calculation method by whichintegrates from the start to the end of the R2* (t) curve first-passbolus, using the baseline subtraction method from T2/T2*—weightedleakage correction [18], Hu, L. S. et al. (2009) incorporated herein byreference.

Blood Volume

Blood volume is calculated using the area under the contrast curve overtime (AUC), (FIG. 2A-2B). This area represents the total blood volumeincluding the arteries and the veins, although as can be seen, thegreatest contributor to the total volume is the venous volume. Duong etal. [19], incorporated herein by reference, calculated that in thenormal blood volume, the venous space represents 70%, with the arteriescontributing the rest.

Permeability Values

Permeability represents the exchange of fluid or small particles in theintravascular and extravascular spaces. This exchange depends somewhaton the arterial inflow and the venous outflow characteristics but alsoon the nature of the exchange sites at the capillary level. Dvorak [20,21], Nagy [22, 23], and Kohn [24], all incorporated herein by reference,have shown that permeability occurs in venules through fenestra as wellas in the vesiculo-vacuolar transport organelles which traverse thevenous wall. Dvorak [20, 21] and Kohn [24] studied tracer macromoleculartransport across vessels. Nagy et al. [22, 23] studied vascularpermeability in an adenovirus transfected VEGF model and determinedpermeability occurred in veins not arteries using electron microscopy,Evan's blue dye, and albumin dual radiotracers.

Permeability values can be calculated from both CT and MRI, but they aremost commonly used in conjunction with gadolinium-enhanced DCE MRI(dynamic contrast-enhanced magnetic resonance imaging). According toWorkman [16], these are “K^(trans) (min-1), the rate of flux of contrastagent into the extracellular extravascular space within a given volume,or volume transfer constant); v_(e), the volume of the extracellularextravascular space; and k_(ep) (mix⁻¹), the rate constant for the backflux from the extracellular extravascular space to the vasculature.These parameters are related to each other by the equation,k_(ep)=K^(trans)/v_(e).” The mathematical derivations of these valuesare beyond the scope of this commentary, and the reader is referred toseveral excellent reports [16, 17].

Kinetic Curves

A subjective evaluation of the shape of the inflow and outflow portionsof the time contrast curves has been found to be a useful interpretivetool for DCE MRI of the breast. Many sources especially Kuhl [25-27],all incorporated herein by reference, have used analysis of these“kinetic” curves for the diagnosis of breast cancer. However, attemptsto apply these curves to other organ systems have been less successful.

Looking at the curve, FIG. 2a and FIG. 2b , it is apparent that theinflow slope represents the arterial inflow rate. The peak correlateswith the maximal enhancement and the outflow portion reflects venousproperties. In general, the inflow slope has been considered to be lessuseful in the analysis because it is too dependent upon technicalfactors related to contrast injection, e.g. rate, volume, etc. A veryhigh peak is considered a spike if it is 60% above the baseline;although a spike is typically thought of as being characteristic ofarteries, it is apparent that if there is not rapid outflow representingveins, it could not be a spike.

Washout

“Wash out” of contrast material is a simple interpretive sign based onthe observation that an enhancing focal mass quickly shows decreasedenhancement and compared to normal tissue enhancement, it “washes out”earlier. This has been most commonly used with hepatic masses, during abolus of contrast material on DCE MRI, MDCT or ultrasound imaging.

Perfusion Parameters of Different Organ Systems

The literature shows that while the above mentioned parameters dependupon the venous properties, their usefulness in the different organsvaries greatly. For example, permeability or kinetic curve analysis areworthwhile in some organs but not others. The most plausible explanationis of course that the receptors, physiology, chemistry of the organsdiffer greatly so the individual characteristics dictate the vascularproperties.

Brain

Using DCE MRI and bold imaging, numerous sources have reported thatblood volume measurements can be used without factors to predict thedegree of a parotid [28] malignant brain tumor differentiation [14, 15,29-32]. Spampinato et al. [32], incorporated herein by reference,concluded that, “Relative cerebral blood volume measurement and MRS (MRIspectroscopy) are helpful in differentiating low-grade from anaplasticoligodendroglial tumors”, (FIG. 3, FIG. 4A-4B, and FIG. 5A-5B). Jain etal [31], incorporated herein by reference, noted that differentiatinghigh and low grade astroglial tumors was possible using the PS(permeability surface area) and CBV (cerebral blood volume). Hu et al.[33], incorporated herein by reference, reported that cerebral bloodvolume measurements could differentiate high-grade glioma recurrencefrom post-radiation therapy changes.

FIG. 3 shows a scatter plot of relative cerebral blood volume (rCBV)ratios for each tumor shows significant difference between the low-gradeand high-grade oligodendroglial tumors (p<0.05) [32].

FIG. 4A-4B shows a 44-year-old man with low-grade oligoastrocytoma.T2-weighted image. FIG. 4b Relative cerebral blood volume map shows lowtumoral vascularity [32].

FIG. 5a . shows a 64-year-old man with anaplastic oligodendroglioma.FLAIR image corresponding to A shows a right frontal cortex-based mass(arrow). FIG. 5b . Relative cerebral blood volume map shows elevatedtumor vascularization of tumor. [32].

Breast

To diagnose breast cancer using MRI, kinetic curves and permeabilitymeasurements have become widely accepted as useful diagnostic tools forboth diagnosing and characterizing breast cancer. When the morphologicMRI appearance is not diagnostic, kinetic flow curves fromgadolinium-enhanced dynamic contrast MRI have been proven quite usefulfor differentiating cancer from a benign lesion [25-27, 34-37],incorporated herein by reference. Kinetc curves can be interpreted byvisual analysis; however, computer software programs facilitate theiruse.

The appearance of the contrast time-flow curves has been well describedby Kuhl [25-27] and others (FIG. 6, FIG. 7, FIG. 8A-8B and FIG. 9) forbenign and malignant lesions. According to Kuhl, cancer has twocharacteristic appearances, i.e. the rapid contrast spike and theappearance of the outflow curve.

The rapid enhancement spike is considered cancerous if the rapid earlypeak is 60% above the baseline (FIG. 2A-2B). Although there are only afew comments regarding the outflow curve of a spike, it is quite evidentthat the spike appearance depends upon rapid outflow (due to veins) aswell as on rapid inflow.

When there is not a spike, correct diagnosis depends upon the shape ofthe outflow curve, which reflects venous drainage, (FIG. 6, FIG. 7, andFIG. 8A-8B). Benign lesions typically have a kinetic curve which showsan increase or plateau flow, Ia and Ib. Cancer shows a decreasing“washout” type II and type III, (FIG. 6). The outflow characteristicsare determined by venous flow, permeability, and arteriovenous shunting[25-27, 38]. The steeper the outflow slope the more likely it is thatthere is cancer. For the best results, careful attention must be givento detail and the appearance of the kinetic curve; Comprehensivediscussion of the technique should be reviewed in the article by Kuhl etal. [25-27], (FIG. 9).

FIG. 6 shows a schematic drawing of the time-signal intensity curvetypes. Type I corresponds to a straight (Ia) or curved (Ib) line;enhancement continues over the entire dynamic study. Type II is aplateau curve with a sharp bend after the initial upstroke. Type I is awashout time course Kuhl et al., [25].

FIG. 7a and FIG. 7b show a region of interest (black oval on the leftimage) and corresponding time signal curve of an enhancing mass in theright breast, with an irregular shape, speculated borders, heterogeneousinternal enhancement, and first initial enhancement followed by earlywashout. The mass was determined to be Bi-Rads category 5, as themorphologic and kinetic criteria were both highly suggestive ofmalignancy Kuhl et al., [26].

FIG. 8A-B shows a Myxoid fibroadenoma. (FIG. 8a ) Region of interest(black oval on the left image) and (FIG. 8b ) the correspondingtime-signal intensity curve. The mass has a lobulated shape, smoothborders, heterogeneous internal enhancement with dark internalseptations, and fast initial enhancement followed by persistentenhancement. The mass was determined to be BI-RADS category 2, as themorphologic and kinetic criteria were concordantly benign, Kuhl et at,[26].

FIG. 9 shows a computer evaluation of kinetic curves is more consistentand convenient. This graph shows three curves measured at differentsites in the same breast cancer, and displaying some variability butstill showing the characteristic cancer signature of rapid washout. Notethat the inflow curve is quite steep, and it is because of the shape ofthe outflow that this is not a “spike.” Spike enhancement also dependsupon the venous outflow.

Changes in kinetic curves are also useful for assessing treatmentresponse, as they show the early changes in the washout curve (FIG. 10).Kuhl et al. [25-27] stated: “As the earliest sign of response, a changeof enhancement kinetics was observed (slower wash-in rate, absence of awashout pattern—ie, flattening of the enhancement curve), which precededa change in tumor morphology by several weeks.”

Permeability measurements have proven quite useful for the diagnosis andtherapeutic follow-up of breast cancer. Radjenovic et al. [39],incorporated herein by reference, found, that “Parameters k_(ep) andK^(trans) were significantly higher in Grade 3 tumours than in low-gradetumours.”

When an untreated tumor shows increased permeability, anti-VEGF drugschange the permeability and kinetic curve [40-42], all incorporatedherein by reference. Raatschen et al [40] concluded that, “The MRimaging-assayed acute change in vascular leakiness after a single doseof bevacizumab was an early, measurable predictive biomarker of tumorangiogenesis treatment response”, (FIG. 11). Thukral et at [42] reportedthat with effective treatment with bevacizumab, the permeability Ktransand blood volume changes were statistically significant, (FIG. 11).Basic science reports by Jain [14, 15] and Boucher [43, 44],incorporated herein by reference, have confirmed that the increasedpermeability and interstitial edema are reduced by the effects ofanti-VEGF.

Important to the ALPHA thesis is that the VEGFR receptor sites areproducing permeability on the peripheral veins at the margin of tumors[20-25]. The location of the action sites of VEGF and anti-VEGF drugs onveins explains the increased incidence of the venous thromboembolismreported by Nalluri [11] and using anti-VEGF drugs.

FIG. 10 show a change in serial transverse GKM K^(trans) parametric maps(calculated from the transverse T1-weighted spoiled gradient-echosequence {8/4.2, 25° flip angle, 4-5-mm section thickness}) (images atthe top) and in the gadolinium (Gd) concentration-time curves (graphs atthe bottom) for one patient from baseline to cycle 7 (C7). Tumorenhancement in the involved breast can be seen in the following colors:Red and green indicate high enhancement, and blue indicates lowenhancement. Gadolinium concentration-time curves show the rate ofgadolinium-based contrast material perfusion throughout the tumor. Theblue line represents arterial input function (Alfn). ROI data, CI=cycle1, C4=cycle 4, LMB=left mouse button, RMB=right mouse button Thurkal etal. [42].

FIG. 11 show the graphs illustrating the absolute decreases in K^(trans)from the baseline to cycles 1 and 4. Two-sided P values were calculatedwith the Wilcoxon signed rank test (P=0.003 for the difference inK^(trans) between cycle 1 and the baseline, P<0.001 for differencebetween cycle 4 and baseline). The horizontal line inside each boxrepresents the median quartile, the horizontal line below the box is thelower quartile, and the line above the box is the upper quartile. Thevertical lines connect the quartiles, Thurkal et al., [42].

Prostate

Early reports on the usefulness of MRI of the prostate, were less thanenthusiastic [45, 46], incorporated herein by reference, although therehave been subsequent reports of considerable success in both thelocalization and differentiation of normal from cancerous tissues[47-51], incorporated herein by reference. Blood volume and kineticcurves [52], incorporated herein by reference, have not beenconsistently helpful, although permeability characteristics are quiteuseful. Jackson et al. [47] indicated that “quantitative parameter mapsshowed a significant difference between the benign peripheral zone andtumour for the parameters K^(trans), v_(e) and k_(ep).”

Liver

Washout or rapid clearance of intravenous contrast material after thepeak enhancement has proven to be a reliable indicator of malignancy.This interpretative sign has been used with ultrasound, CT, and MRI anddepends upon the rapid clearance of contrast material through tumors ascompared to through normal liver.

With microbubble-enhanced ultrasound, sources [53-57], incorporatedherein by reference, reported that HCC could be characterized by delayedwashout after early enhancement. Jang et al. [53, 54] used ultrasoundwith microbubble-contrast material to study 97 hepatocellular cancers.Jang et al. [53, 54] reported that 43% showed washout by 90 seconds, 26%washed out at between 91-180 seconds, and 22% washed out in 181-300second period. Only 8% of cancers showed no washout and they were welldifferentiated HCC's.

Sources [58-60], incorporated herein by reference, reporting ongadolinium-enhanced MRI indicated that washout could distinguish benignand malignant lesions (FIG. 12A-12C). After studying 70 nodules, Ito, K.et al. (2004) [61], incorporated herein by reference, stated, “Rapidcentral washout after the early enhancement of the lesion and coronalenhancement surrounding the lesion are highly specific and diagnosticfindings of small hypervascular hepatocellular carcinomas.”

FIG. 12A-12C shows a gadolinium-enhanced MRI of liver metastases showingwashout characteristic of malignancy. FIG. 12A. shows multiple subtlesmall masses (arrow) before enhancement. FIG. 12B. During gadoliniumadministration, these lesions showed increased enhancement. FIG. 12C.The lesions showed contrast washout at 70 seconds after contrastinjection.

Multiple sources [62, 63] using MDCT reported the value of the washoutsign. Lee et al. [63] reported, “Both subjective and objective washoutcorrelated with an elevated alpha-fetoprotein level (p=0.01).”

Re-Examination of Seminal Gimbrone/Folkman Vasculogenesis Report

Finally, retrospective review and reinterpretation of the originalvasculogenesis report by Gimbrone and Folkman [4] revealsinconsistencies (FIG. 4A-4B). Case Western Reserve Engineering schoolscientists, Dean and Professor Norman Tien and Professor Vera Chankong,re-analyzed all of Gimbrone's published 10 experiment data set, relativeto the single “representative” graph from one animal. Tien and Chankongconcluded with 95% certainty that the initial rapid tumor growthpreceded arterial flow by at least one day.

FIG. 13A shows “The characteristic growth curve of an iris implant (BPNo. 29R) plotted on a semi-logarithmic scale. Positive fluorescein teston day 6 represents earliest evidence of perfusion of the tumor andcoincides with the beginning of exponential volume increase. Slopes “a,”“b,”, and “c,” corresponding to prevascular, vascular, and late phasesof growth, are indicated.” Note the arrow indicating the arterial flowoccurs after the rapid growth is initiated, Journal of ExperimentalMedicine, 1972; 136, p. 261-76 [4]. As discussed, statistical analysisof ten data sets, published but not used in this single graph revealsinitiation of rapid tumor growth preceded arterial flow by at least oneday. Therefore, the cause of the interruption of dormancy and growthcannot simply be elimination of hypoxia by arterialization.

FIG. 13B. Diagram shows an overlay over the original Gimbrone diagramillustrating the ALPHA concept. The contention being described herein isthat the dormancy can only be explained by high lactate levels which mayexist with or independent of hypoxia via aerobic glycolysis (glycolysisoccurs in inflammatory, immune, or cancer cells even in normoxia). Whenhigh lactate levels produce dormancy reduction to moderate levels bylymphatics and veins interrupt tumor dormancy. As will be noted later,lymphatics and veins develop before arteries [20].

III. Cancer Metabolism: Energy Production, Waste Management, Glucose andOxygen Availability, Disadvantages and Advantages of Aerobic andGlycolytic Metabolism

Cancer consumes glucose by aerobic and/or glycolysis (anaerobic)processes [64-67], incorporated herein by reference. Aerobic metabolismusing glucose and oxygen occurs in mitochondria while glycolysis usingonly glucose without oxygen occurs in the cytoplasm.

Warburg [66], Pederson [67] and others have reported that glycolysis isthe preferred metabolic path for cancer. Pederson [67] noted that evenin normoxia 50% of cancer metabolism can be from glycolysis and is evengreater in hypoxia.

Benefits of glycolysis and lactate are numerous. Glycolysis stimulatesthe production of critical substrates for cell proliferation (such aspentose from PPP pathway, acetyl-CoA, NADH). Acidic lactate 1) creates aselective adaptive environment which kills normal cells and selectscancer clones with specialized waste enzymes (carbonic anhydrase IX,CAIX), monocarboxylic transporter 4, MCT4), 2) induces hyaluronan whicha) activates motogenic genes by cell membrane attachment and TGFb, b)hyaluronan stabilizes the mitotic spindle so aberrant clones canreplicate, c) hyaluronan gradient aligns lymphatic endothelial cells viaLYVE-1, a hyaluronan receptor, 3) induces TGFb which activatesmetalloproteases (Bauman 2009)[68], 4)Combination of MCT4, hyaluronandependent molecule CD147 (Tang 2004 [69], Le Floch 2011 [70]) activatesanti-apoptotic pathways including NFkB (Brown 2008 [71]), 5) acidiclactate releases VEGF and FGF from heparin sulfate and induces NFkBvasculogenic cytokines. (Brown 2008 [71]) 6) lactate induced specificcytokines 17/23 induce VEGF (Shime 2008 [72]) 7)induce COX2 stimulatingVEGFC/D and cancer supporting prostaglandin E2.

Energy and Waste Production

Metabolism of glucose in normal and cancerous tissues occurs by twopathways, glycolysis and aerobic metabolism. Glycolysis creates ATPenergy and pyruvate from glucose without oxygen. In the normal state,pyruvate moves into mitochondria to be processed with oxygen through theKrebs cycle. In the cancerous state, most pyruvate does not enter theKrebs cycle but is predominantly changed into lactate. In the cancerousstate, the lactate feed back controls are altered and all pyruvate iscompletely converted into lactate by the cancer enzyme lactatedehydrogenases A [63]. The excessive lactate is detrimental to normalcells but cancer cells are unaffected because of specialized enzymeswhich protect the chemical balance of cancer cells.

Advocates of the current angiogenesis theory infer that the aerobicpathway should be preferred because of the efficient use of glucose, butWarburg [66] and others have confirmed that glycolysis is the preferredmetabolic pathway for cancer. While glycolysis is chemicallyinefficient, it suits cancer well because its reaction speed is 100times faster than aerobic processes and can generate ample energy. Veryhigh lactate levels may cause cancer cell dormancy, but moderately highlevels provide many benefits as noted below.

Taking a different perspective in examining the energy and wasteproduction by the two metabolic pathways, a different teleologicrationale for angiogenesis related to glycolysis can be proposed.

With aerobic metabolism, one molecule of glucose and one molecule ofoxygen produce 38 ATP's and C02 molecules. Glycolysis uses one moleculeof glucose and no oxygen to make 2 ATP's and 2 lactates. Assuming a cellneeds 38 ATP molecules to sustain life, a cancer cell would require 19molecules of glucose and no oxygen to produce 38 ATP's which would alsocreate 38 lactate molecules.

From this perspective and data, it is difficult to accept the currentteleologic rationale that cancer angiogenesis is intended to growarteries for improved oxygenation. The more logical teleologic rationalewould be that if cancer has adequate glucose supply for glycolysis, itsearliest immediate vascular need is to grow drainage vessels to removethe waste products rather than arteries to improve oxygen delivery.

Cancer's increased requirement for glucose is clinically confirmed bythe characteristic images produced by FDG (fluorodeoxyglucose) PET(positron emission tomography imaging. The rapid turnover of glucoseappears as an increased signal indicating hypermetabolism, (FIG. 14).FIG. 14 shows a FDG PET scan of metastatic colon cancer in the liver.The lesions (arrow) show increased signal because more glucose must beprocessed for the same amount of energy, (see text).

Experimental and clinical reports confirm when both aerobic and aerobicmetabolism are used by cancer, the overall metabolism is more dependentupon glucose than oxygen supply. Eskey et al. [73], incorporated hereinby reference, elegantly confirmed the importance of glucose over that ofoxygen for cancer metabolism. They used an animal model with anexteriorized tumor and separately varied the inflow of oxygen andglucose while they measure the effects on energy production. Energyproduction was directly related to glucose supply but not oxygen supply.Lui and Matsui [74], incorporated herein by reference, reported aninteresting model which can be used to speculate further about glucosesupply over arterial oxygen supply. In a mouse model, tumor cells wereinjected into an exteriorized live and observed with videomicroscopy.The first vessels to develop in the tumors was the portal vein, i.e.high glucose, followed later by the arterial system [74].

Clinical reports [75-78], incorporated herein by reference, confirmedthe lack of correlation between oxygenated blood flow and energy innumerous PET studies. Vaupel et al. [79], incorporated herein byreference, reported lactate production is directly correlated withglucose uptake, as 40-85% may be released as lactate.

Adequate Glucose Supply is Provided without Normal Arterialization byEffective Diffusion and Active Glucose Transporters (GLUTS)

Certainly at the organ level, arteries are necessary to supply theinflow of glucose, but the movement of glucose across tissues and cellsis quite efficient, without normal arterial supply. The effect of theincreased distance between tumor and arteries on the supply of glucoseand oxygen has been discussed by Gilles [80] and Gatenby [81],incorporated herein by reference. Gilles et al [80] reported (FIG. 14),that when the distance from arteries to tumors is more than 100-150microns, the oxygen supply is restricted because of its poor diffusion.This hypoxia prevents aerobic metabolism.

Conversely, under the same circumstances the glucose supply isunaffected because of its favorable diffusion properties and activetransport by glucose transporters (GLUTS). These up-regulatedtransporters are part of the metabolic adaptation (as well as wasteenzymes) supported by HIF1a to initiate and support metabolic adaptationto glycolysis.

FIG. 15 shows substrate and metabolic profiles found in premalignantintraductal tumor using reaction-diffusion modeling. Oxygenconcentrations (solid line), glucose concentrations (dashed line), andH+ concentrations (dotted line) are shown, from Gillies and Gatenby, JBioenerg Biomembr (2007) 39:251-257 [80],

Depending Upon Concentration: Moderate Lactate Elevations EnhanceMetastatic Properties and High Levels Induce Dormancy

Although not generally recognized, molecular or drug effects can varyaccording to the concentration. An excellent clinical example isDopamine, which affects blood pressure differently with differentconcentrations. Likewise, moderate or high elevations of lactate affectcancer cells differently. At moderately high levels, the neoplasticproperties are enhanced and at very high levels, dormancy is induced.Whether dormancy is a positive or negative process depends upon thecircumstances for the cancer cells.

Moderate Lactate Elevation/Low pH Provides Advantages for Cancer

If lactate is maintained at moderately elevated levels, there areadvantages for cancer survival, proliferation and metastases. Moderatelactate levels create a locally hostile environment with low pH, toxicto normal cells to which, cancer cells can adapt by genetic mutation andsurvive [82], incorporated herein by reference. To ensure suchadaptation, HIF has been recognized as critical for several dozen targetgenes that are transactivated by HIF-1 have been identified, includingthose encoding erythropoietin, glucose transporters, glycolytic enzymes,and vascular endothelial growth factor. The products of these geneseither increase O₂ delivery or allow metabolic adaptation to reduced O₂availability [83], incorporated herein by reference. While hypoxia isthe best recognized inducing agent for HIF, other factors such aslactate [84, 85], incorporated herein by reference, and metabolicintermediates could increase HIF levels (see angiogenic mediators inFIG. 16).

FIG. 16 shows a map of peritumoral H⁺ flow using vectors generated fromthe pH, distribution around PC3N/Efgp. The tumor is the darker region(left) and the tumor-host interface is drawn based on the GFP image.Arrows indicate the direction of H (the steeper the gradient, the longerthe arrow). Note the general flow of H⁺ from the tumor core to itsperiphery, and from there, into the normal tissue, although there issignificant heterogeneity, Gatenby, Cancer Research, 2006, vol. 66, May15, 2006 [81].

Such clones possess specialized waste enzymes, such as carbonicanhydrase IX and lactate transporters increase the acidic environment,activating enzymes which enhance local invasion, FIG. 16. Unusual cloneswhich might not be capable of normal mitotic division can successfullyreproduce because the mitotic spindle is stabilized by the moleculehyaluronan which is induced by lactate [86], incorporated herein byreference, (FIG. 16).

Metastatic potential is enhanced by lactate because of numerous effects.Cancer cells and endothelial cells become capable of “locomotion” whenthe hyaluronan molecule (induced by lactate) attaches to the RHAMMreceptor of the cell wall. This action signals the cytoskeleton totransform and produce the contractile protein actin [86] (FIG. 16).Lymphatic channels form from lymphatic endothelial cells with the uniquebiomarker hyaluronan receptor 1 (LYVE-1) Lymph cells under the influenceof VEGF3, align according to the hyaluronan gradient (see latertransformation section). Hamilton et al. [87], incorporated herein byreference, reported that hyaluronan sustained high basal motility inbreast cancer. The large amounts of lactate produced increasedinterstitial fluid pressure which creates convective current towardlymphatic channels [88], incorporated herein by reference.

FIG. 17A-17B shows hyaluronan attaches to the cell membrane receptor,RHAMM, thus permitting transcription of motogenic genes. Hyaluronanstabilizes the mitotic spindle, thus permitting more effective celldivision and mitosis. Extracellular and intracellular functions of RHAMMare: (FIG. 17A) Cell-surface RHAMM promotes the activation of signalingcascades. Shown is one molecular mechanism for this. Cell-surface RHAMM,which is not an integral membrane protein, partners with CD44 and, inthe presence of hyaluronan, activates ERK1/2 (indicated asphosphorylated (PO₄) ERK1,2), which results in the expression of genesthat are required for motility and invasion. (FIG. 17B) In X, laevis eggextracts, a RAN-GTP gradient, which is established by chromosome-boundguanine nucleotide-exchange factor RCCI activity, is required foranastral mitotic-spindle assembly. RAN-GTP activity regulates thefunction of a number of mitotic-spindle proteins, including importinsthat then form inhibitory complexes with both spindle-assembly factorsand TPX2. For example, by binding importins (indicated as step 1),RAN-GTP releases TPX2 (step 2), which is a major activator of Aurorakinase A (AURKA). TPX2 directly activates AURKA by protecting anautophosphorylated residue (step 3). AURKA, in turn, can phosphorylate(PO₄) BRCA1 to facilitate G2-M transition (step 4). Via an interactionwith the dynein complex, RHAMM localizes to the spindle pole, at whichit interacts with 7-tubulin (step 5). RHAMM also interacts with TPX2 anddynein, thereby having the potential to localize TPX2 to spindle poles(step 5). The BRCA1-BARD1 complex modifies TPX2 localization and spindleassembly by attenuating RHAMM function through ubiquitylation (Ub) (step6). Ubiquitylation of RHAMM, and subsequently its degradation, probablyreleases TPX2 from the spindle pole (step 7), thus affecting AURKAactivation and G2-M progression.

Tumor Dormancy

Dormancy of cancer cells is an inactive state from which tumor cellsmust emerge to grow, proliferate, and metastasize. Because interruptionof dormancy has been the benchmark to judge effective vasculogenesis, abetter understanding of its causative mechanisms is important. Becausethe traditional angiogenesis theory is derived from Gimbrone et al.inferring hypoxia causes dormancy and restoration of oxygen interruptsdormancy, it is interesting to note their direct statement [4]. Gimbroneet al. stated,” “The mechanism of this population dormancy is notelucidated by these experiments.” [4].

Surprisingly, direct data about hypoxia adversely reducing cancer cellactivity leading to dormancy is not only lacking but there is abundantcontrary information. Voluminous data indicates that hypoxia enhancesthe invasive metastatic process which is the essence of malignancy itdoes not retard such processes. As has been discussed, lactate that isproduced by hypoxia produces lactate that enhances motility, mitosis,and local invasion as noted.

However, increased lactate levels, which is produced by cancer in eitheraerobic or hypoxic environment, has been reported to produce effectsthat would support dormancy, i.e. slowed metabolism, decreasedproliferation, and anti-apoptotic effects. These data come from basischemistry, simple cell culture experiments, clinical studies, and somespecific signaling pathways.

If one considers the basic mass action dynamics of chemistry, the excessaccumulation of an end product will decrease the forward reaction bymass action effect in reverse. Hence because cancer uses glycolysis,accumulation of lactate would decrease metabolic rate [89-93],incorporated herein by reference. Excess lactate impairs proteinsynthesis, growth and antibody production [88]. It also reduces cancercell proliferation [90, 93].

Until this time, lactate was not evaluated as a possible cause ofdormancy. Basic research has been down relative to the signalingpathways but there are a number which support this premise becauselactate and glycolysis has been shown to prevent cell death byanti-apoptotic pathways. One of the major death pathways, FAS wasreported by Erkilla [94], incorporated herein by reference, to besuppressed in germ cells by lactate. Erkilla [94] stated, “The finalsite of the death suppressing action of lactate appeared to take placein germ cells downstream of the FAS receptor activation.” Thangarju etal. [95], incorporated herein by reference, studied the effect oflactate on the SLC5A8 trigger pathway for tumor cell apoptosis. Becausethis pathway depends upon pyruvate, they stated, “Tumor cells silenceSLC5A8 and convert pyruvate into lactate as complementary mechanisms toavoid pyruvate induced cell death. The important inflammatory pathwayNFkB is known to induce anti-apoptotic genes Bcl-3, IAP-1, and IAP-2[71], incorporated herein by reference. Samuvel [96], incorporatedherein by reference, reported that lactate boosts TLR4 signaling andNFkB pathway mediated gene transcription in macrophages. Also COX2 isup-regulated by NFkB and COX2 inhibits DNA damage induced apoptosis byp53 [97], incorporated herein by reference.

To understand causes of dormancy, changes in cell cycle control wouldneed to be elucidated according to Blackstone [98], incorporated hereinby reference. Rutz [99], incorporated herein by reference, noted“lactate interferes with mechanisms of cell-cycle control at twodifferent points in the cell-cycle, depending on cell density and theresulting absence or presence of inhibition of cell proliferation.Interference with cell-cycle control may underlie the modification byexogenous lactate of radiosensitivity and postirradiation repaircapacity in mammalian cells.” Also several other papers suggest theremight be a relationship between lactate and the chief regulator of cellcycle, pRb (protein retinoblastoma). Lactate induces and modulates bothTNF (and TGFb, which have their own interaction) [100-102], incorporatedherein by reference, which TGFb interacts with pRb [97]. If ALPHA ismore completely investigated, perhaps other pathways related to cellcycle arrest will be elucidated. Glycolytic enzymes related to lactateand the Akt pathway is also known to inhibit apoptosis [98, 103].

There has been extensive study of tumor recurrence and its dependency ondormancy [71] but in clinically oriented reports there is an obviouslack of discussion about hypoxia. Blackstone et al. [98] extensivelydiscussed tumor dormancy/recurrence and emphasized the importance ofcell cycle pathways (no mention of hypoxia even after 40 years ofstudy).

Other clinical reports are more consistent with lactate induced dormancyas it relates to cancer recurrence and treatments. Recognizing thatdormant cells do not respond well to treatment, several sources havenoted that treatment resistance may be associated with elevated lactateand that restoration of normoxia does not increase recurrence. Quennetet al. [104] and Sattler [105], both incorporated herein by reference,noted correlation between radioresistance and glycolysis and acidiclactate concentration. Feldmeyer [106] and Schonmeier [107], bothincorporated herein by reference, dispelled the concern that tumor cellswould be activated by restoration of normoxia by hyperbaric oxygen. Bothsources found no increased local tumor recurrence as would be expectedfrom the currently accepted concept that hypoxia causes tumor dormancy.

Lactate Level of Interstitial Fluid Modulated Predominantly byLymphovenous Drainage and Partially by Aerobic Metabolism of Stromal orCancer Cells

After recognizing the cancerous processes controlled by elevatedglycolytic lactate, in hypoxia (anaerobic) or normoxia (aerobic), theimportance of maintaining appropriate levels can be appreciated.Increased glycolytic activity produces excessive lactate in theextracellular space producing increased interstitial pressure [108],incorporated herein by reference. This occurs because the 6 carbonglucose being split into two carbon lactate doubles the oncoticpressure. With convectional movement of free water [79] into the sitehydrostatic pressure is produced stimulating flow into the lymphatics.Lactate levels depend predominantly upon the removal of lactate by thelymphatic and venous system.

Earlier studies by Gullino [88] on lactate reported that tumorinterstitial fluid always had higher lactate than that of the inflowwith the concentration being 25-100% higher. From baseline levels, thetumor levels increased until about 10 days when the levels werestabilized and maintained. Lymphatic drainage consistently measured 2-4times that of tumor interstitial fluid. Studying a de novo squamous cellcancer model in mice, Eitchen et al. [109] verified that interstitialfluid was maintained by lymphatic flow. In the transition from normal topremalignant state, the host lymphatics dilated and increased in sizedue to the effects of VEGF-C. With the development of squamous cancer,the fluid increased and neolymphangiogenesis occurred, (see laterLymphangiogenesis section). Such lymphatics induced by VEGF-C are knownto cause early local metastases [110, 111], both incorporated herein byreference.

The only incidental advantage of aerobic metabolism for cancer cells isindirectly related to lactate reduction by aerobically competent cells.When cancer cells retain mitochondria and oxygen is available, lactateis consumed, reducing local levels [112], incorporated herein byreference. Similarly, Kourakis [113], incorporated herein by reference,emphasized that adjacent stromal cells could reduce local lactate and pHlevels, by metabolizing lactate.

FIG. 18 show a CT scan showing a mass in the medial side of the breast,horizontal arrow as well as early metastases to small axillary node,vertical arrow. Hyaluronan, which is produced by breast cancer, andfibroblasts stimulate cancer cell migration, and enhance mitoticactivity and lymphatic development. Hamilton et al. [87] reportedhyaluronan maintained breast cancer cell motility.

Lactate and Low pH Induce Vascular Growth Factors which InduceLymphanglogenesis, Venogeneais, and Arteriogenesis

As will be discussed in subsequent sections, virtually all of theangiogenic growth factors are released and/or produced by the effects oflactate and low pH. The processes include both the release of dormantgrowth factor in the microenvironment and production of new factors madeby numerous cells. The stimulus for the production is the transformationof the microenvironment through numerous pathways most importantlythrough the TGF (transforming growth factor) by means of NFkB (nuclearfactor kappa beta) pathway. The transformation includes endothelialcells, cancer cells, stromal fibroblasts and many immune cells.

There are No Real Advantages of Aerobic Metabolism for Cancer

The only incidental advantage of aerobic metabolism for cancer cells isthat local lactate levels are reduced when adjacent aerobic cancer orstromal cells metabolize lactate [112-114], incorporated herein byreference. As discussed earlier, some sources refer to the chemicalefficacy of aerobic metabolism but the fast reaction speed of glycolysismore than compensates to produce ample energy.

IV. Signaling Pathways, Vascular Growth Mediators, Action Site ofMediators for Lymphatics, Veins, and Arteries Signaling Pathways forAngiogenic Growth Mediators

One of the most prevalent misconceptions supporting the currentangiogenesis concept is that hypoxia is the sole mediator for VEGF andother vascular mediators. As will be discussed later, angiogenic growthmediators are induced by hypoxia but also many other pathwaysindependent of the oxygenation level, i.e. normoxia, and hyperbaricoxygen. Among these other pathways lactate and low pH have beenextensively discuss in the literature, especially in the early stages ofangiogenesis and in wound healing.

Anglogenesis Growth Mediators are Induced in Hypoxia, Normoxia, andHyperbaric Oxygen

A most intriguing study by Heinzman et al [115], incorporated herein byreference, demonstrated that the production of many angiogenic growthfactors is essentially equivalent in both hypoxia and normoxia. Cancercells in hypoxia or normoxia produced almost equivalent amounts ofangiogenic growth factors. Heinzman et al. [115] quantitated 11angiogenic growth factors (VEGF,PDGF-AA, PDGF-AA/BB, IL-8, bFGF, EGF,IP-10, Flt-3 ligand, TGF-b1, TGF-b2, and TGF-B3) produced by differentcancer cell lines in hypoxia and/or normoxia. Comparing the angiogenicproducts, they showed no or only a moderate increase of VEGF and nosignificant increase in bFGF in hypoxia. Of the other products, onlyIL-8 was generally higher and the levels in 8 of 11 mediators wereclosely correlated.

Hypoxic expression levels were generally higher than normoxic for IL-8(r²> and VEGF (r²>0.60), although only modestly. Heinzman [115] noted,“The degree of difference was surprising, as both IL-8 and VEGF havebeen reported to be up-regulated in response to hypoxic conditions.” “Itis remarkable to note that hypoxia did not increase bFGF compared tonormoxia. Another in vitro study showed that bFGF was unaffected byhypoxia in cell lines” [116], incorporated herein by reference.

Reports regarding angiogenesis in hyperbaric oxygenation provide uniqueevidence indicating that factors other than oxygen levels areresponsible for angiogenesis. In his study of squamous cell cancer,Schonmeyr et al. [107] observed that hyperbaric oxygen eliminatedhypoxia and restored normoxia in squamous cell tumors. They unexpectedlyfound that with the restoration of tumor hypoxia to normoxia the amountof VEGF and vessel growth did not change compared to the precedinghypoxic state.

Signaling Pathways for Angiogenesis Include HIF (Hypoxia InductionFactor), Acidic Lactate and Other Pathways

HIF-1a (Hypoxia Induction Factor) is the most important regulator forVEGF and FGF and well as most of the other enzymes which supportglycolysis and the neoplastic processes. Although infrequentlydiscussed, other processes affect HIF concentration. Of special note isthat the increases of HIF can also be caused by non hypoxic intermediarymetabolic imbalances [37, 72, 117-119], incorporated herein byreference. In addition to up-regulating angiogenesis, HIF is absolutelycritical for adapting cellular metabolic processes to glycolysisassociated with hypoxia or aerobic glycolysis [120]. In addition toup-regulating angiogenesis, HIF is absolutely critical for adaptingcellular metabolic processes to glycolysis which is essential in hypoxiaand also occurs with cancer it normoxia [114]. Interacting with cMyc,these include processes for substrate transport, expedited PPP pathways,rapid conversion of pyruvate to lactate and waste product management tomaintain suitable cellular pH. These include enzymes involved with PPPcycle such as ketolases, glycolysis such LDHA, glucose transporters(GLUT I, II, IV), and waste enzymes carbonic anhydrases IX and XII, andlactate transporters MCT1,4 [83, 84].

The best described and recognized mechanism for controlling HIFconcentrations is regulated by the degradation enzyme PhD (prolyldehydrogenase). The enzyme increases in normal oxygen reducing levelsand decreases in hypoxia to increase the HIF levels [83].

Less well known to most investigators is that HIF can be increased bynon hypoxic intermediary metabolic imbalances [85, 121-123],incorporated herein by reference, and even low pH [124]. Lu et al. [122]stated, “with aerobic glycolysis (not aerobic metabolism but glycolysisin presence of oxygen), glucose metabolites can up-regulate HIF levelsby preventing its degradation.” McFate et al. [123] noted, “these datasuggest that the buildup of glycolytic metabolites, resulting from highPDK-1 expression, may in turn promote HIP-1 activation, thus sustaininga feed-forward loop for malignant progression. ‘Furthermore, Mekhail etal. [125], incorporated herein by reference, reported that as a resultof the low pH induced predominantly by lactate, that “a decrease inenvironmental pH triggers the relocation of VHL (also degrades HIF),neutralizing its ability to degrade nuclear HIF even in the presence ofoxygen.”

Walenta [84] stated, “Demonstrating various biologic activities oflactate that can enhance the malignant behavior of cancer cells. Thesemechanisms include the activation of hyaluronan synthesis by tumorassociated fibroblasts, up-regulation of VEGF and of HIF-alpha, anddirect enhancement of cellular motility which generates favorableconditions for metastases.”

Signaling Angiogenesis Pathways Other than Hypoxia and Waste Products

Recognizing the essential role of vasculogenesis for the success oftumors, it is no surprise there are many redundant vasculogenicpathways. Many diverse induction factors include hypoglycemia [45, 126],genetic anomalies i.e. VHL, PTEN, p53, RAS and oncogene [127-132],incorporated herein by reference. A complete discussion of these manyfactors is not possible nor is it relevant to the purpose of proposingan alternate angiogenesis concept to interrupt tumor dormancy.

Lactate and Low pH Increase Vascular Growth Mediators Independent ofOxygenation Level

Although it is has not become widely known, there are many reportsconfirming that both lactate and low pH induce angiogenic growthfactors. The origins of the acidic lactate are both macrophages andcancer cells which use glycolysis even when oxygen is present (aerobicglycolysis simply means oxygen is present with glycolysis). As notedabove elevated metabolites especially lactate increases HIF as discussedabove even in normoxia. When hypoxia occurs, even more acidic lactate isproduced which likely acts in synergy with the HIF degradation enzymePhD to elevated HIF further.

There are two mechanisms which increase local VEGF levels, the releaseof dormantly store VEGF and FGF [133-135], incorporated herein byreference, and the active production. First in early angiogenesis beforehypoxia (see angiogenesis below) there is the release of dormant FGF andVEGF stored in the heparan sulfate matrix. In the later hypoxic phasethe up-regulation of many other pathways occur from the effects ofacidic lactate which is amplified and synergized by hypoxia.

It is odd that although many sources over many years have reported thatlow pH and lactate can increase vascular mediators, it has not becomegenerally recognized [85, 100, 133-144], incorporated herein byreference. To amplify these facts and to forestall any concerns aboutparaphrasing errors, direct “quotes” are provided. If this exercise istedious, the reader is invited to move to the next section.

D'Arcangelo et al. [133] reported “Acidosis Inhibits Endothelial CellApoptosis and Function and Induces Basic Fibroblast Growth Factor andVascular Endothelial Growth Factor Expression.

Hunt stated [85], “Lactate, on the other hand is also a known instigatorof cytokines and growth factors such as VEGF, TGF-β, and IL-1. Lactatestabilizes HIF-la even in the presence of oxygen because lactate andpyruvate bind to and inhibit the HIF prolyl hydroxylases that wouldotherwise hydroxylate HIF-la and mark it for rapid degradation.”

Fukumora et al. stated [134], “VEGF-promoter activity increased, with adecrease in pH and independent of pO₂.” “VEGF transcription in braintumors is regulated by both tissue pO₂ and pH via distinct pathways.”

Xu et al. noted (140) that “acidic extracellular pH induces VEGF . . .via ERK1/2 MAPK signaling pathway.” Kato et al. [137] stated, “AcidicpHe has also been shown to increase the expression of platelet-derivedendothelial cell growth factor/thymidine phosphorylase, IL-8, and VEGFin varies types of cells.”

Beckert [140] noted that “Lactate induces VEGF synthesis in endothelialcells and that this results in enhanced endothelial cell migration evenin the absence of hypoxia.” “Endothelial cells showed increasedmigration only when lactate was added in combination with endothelialcells” (it is now known lactate activates motogenic genes [86].

The emerging important role of cancer related inflammation and NFkB isenormous, which prompted Colotta et al. to call it the “seventh hallmarkof cancer.” As will be described below, these processes are part of amulti step process, which includes preangiogenic transformation of themicroenvironment, early/incipient as well as delayed/maintenanceangiogenesis.

Samuvel et al. observed, “Lactate boosts TLR4 activation andNF-κB-dependent inflammatory gene expression viamonocarboxylatetransporters and MD-2 up-regulation.” NFkB is the keyorchestrator of innate immunity/inflammation and aberrant NFkBregulation has been observed in many cancers.” Cytokines such as IL-1,IL-6, IL-8, and IL-23 are pro angiogenesis. IL-1 induces FGF2 [63] andVEGF. Mizukami et al. [117], stated “NFkB is induced by hypoxiaspecifically through accumulation of hydrogen peroxide when HIF-1 isblocked, and this compensatory pathway plays an important role tomaintain angiogenesis in the absence of HIF-1 by up-regulating IL-8.Shime et al. [143] reported that lactate through NFkB induced IL-17,IL-23 which are proangiogenic inflammatory cytokines.

V. Modern Immunohistochemical Biomarkers Indicate that Target ReceptorSites of Vascular Growth Mediators

Prior to 2000, it was believed that the lymphatic, venous or arterialcharacter of vessels depended upon the nature, pressure and direction offluid/blood flow. The development of specific immunohistochemicalbiomarkers combined with embryologic studies permits definition of thevascular mediator target receptor sites. Furthermore, retrospectivereview of earlier angiogenesis reports indicates early reportsmistakenly labeled some venous structures as arterial. An excellentreview of vascular specification was reported by Swift [119] in thejournal Circulation Research provides valuable insights forreinterpretation of other reports.

Embryologic Origins of Vessels

The origins of the vascular and lymphatic vessels have beenphylogenetically determined from tissue dissections and theimmunohistologic biomarkers. Both the lymphatics and venous systemevolve from the cardinal veins [120, 145], incorporated herein byreference. The arteries evolve from the dorsal aortas [119].

FIG. 19A-19D shows arterial and venous EC have molecularly definedidentities that are evident before circulatory flow or eventubulogenesis. Expression of artery markers such as ephrinB2a (FIG. 19C)and vein markers such as flt4 (FIG. 19D) is evident by in situhybridization of 25 somite stage zebrafish embryos, several hours beforecirculation begins in the trunk. Expression of EphrinB2a within thedorsal aorta begins just as the migratory EC's arrive at the trunkmidline from the lateral mesoderm and begin to aggregate into a cord ofcells. FIG. 19B shows Expression of the pan-endothelial marker flt 1* isshown for the comparison. Box in upper diagram (FIG. 19A) showsapproximate location of in situ images, for reference. Light arrowsindicate dorsal aorta; dark arrow, posterior cardinal vein. * VEGFR-1 isreceptor for VEGF-A, VEGFR-1 is significantly more enriched in veinsduring early embryologic vessel formation, but later is present in botharteries and veins (personal communication with Brant Weinstein,Director Molecular Genetics Laboratory. NIH). This is consistent withobservations by Dvorak et al. who describe the first changes oftransfected VEGF-A gene on blood vessels is on the venules.

Specification of Vascular Identity by Biomarkers

As a matter of record, specific markers for lymphatics, veins, andarteries have been defined and used in most of the studies referenced.The lymphatic marker is LYVE-1 (lymphatic endothelial cell hyaluronanreceptor site-1). The venous markers are VEGFR1* (flt1), TIE-2, Ephrin4, and COUP TF11. Both VEGFR1 and TIE-2 are very interesting in thatthese have been used by many sources and noted as being arterial markers[12, 146] when in fact they are associated with veins [147]. Moyon[147], incorporated herein by reference, showed that after seven days inthe embryo, TIE-2 specifies veins. Earlier sources, such as Holash [146]assumed that TIE-2 receptor was the target site for angiopoietin was anarterial marker but this is not correct.

Also of note, according to Swift et al, the activation of PI3K/Aktpathway as commonly occurs in cancer, induces venous cell fate. PI3Kpromotes venous fate by suppressing NP1 and Notch gene activation [119,148].

Using these biomarkers, numerous scientists have clarified themechanistic action of the various growth mediators. Furthermore, becauseof the specificity of these markers, the sequence of vessel developmentcan be accurately ascertained.

IV. Animal Models Studying Growth Mediators VEGF, FGF, Ephrin, andOthers Support ALPHA Sequence of Vessel Development

The vascular mediator receptor action sites and the observed sequentialdevelopmental changes in the vessels form an essential basis for ALPHA.As will be noted, the sequence of vascular changes occurs on thelymphatics, veins, and arteries.

VEGF A,-C,-D/VPF

The VEGF (vascular endothelial growth factor) family is the mostimportant group of mediators for vasculogenesis, and consists of VEGF-A,VEGF-C, and VEGF-D.

VEGF affecting angiogenesis originates from two processes. Firstly,release of VEGF from a dormant form in the heparan matrix occurs duringthe early/initial phase of angiogenesis, see transformation sectionbelow. The initial elevation is from the release from the matrix by theeffects of lactate, low pH, and induced inflammation [135, 136, 149,150], incorporated herein by reference. As will be noted later, this mayoccur in hypoxia or normoxia [144, 151]. Secondly, VEGF is produced bytumor-associated cells occurs in hypoxia during the delayed/maintenancephase with other vascular growth mediators [71, 96, 144, 151].

In 1991, using immunohistochemical stains, Dvorak [20, 21] determinedthat the morphogeneic changes caused by VEGF-A is on the host veinsadjacent to the tumor site. Dvorak [20, 21] stated, “Immunoreactivevessels (to VPF/VEGF antibodies) were venules and small veins.” Kohn etal. [24] reported that the permeability of vessels occurred in theveins, and stated, “All tracers leaked primarily from venules and smallveins at the tumor-host interface.”

More recent sophisticated models using a transfected VEGF-A164 gene in amouse model by Dvorak [20, 21] and Nagy [22, 23] studied the developmentof surrogate tumor vessels over a 128-day period. They reported thatvessel morphogeneis occurred sequentially on lymphatics, Veins, andarteries (FIG. 20A-20E, FIG. 21, FIG. 22A-22C, and FIG. 23).

Regarding lymphatic changes, these sources observed that dilatation ofhost lymphatics occurs 1-3 days before blood vessel changes occur [22,23, 109] (FIG. 21). Nagy [22, 23] stated “Lymphatics at 3daysafterAd-VEGF-A are distended from dermal edema but have already enlargedfurther as the result of endothelial cell division and are transitioninginto giant lymphatics.” Eitchen [109] using a de novo skin squamous cellcarcinoma showed lymphatics proliferated and dilated before bloodvessels. Hong et al. [152], incorporated herein by reference, reportedthat the action of VEGF-A promoted wound-associated lymphangiogenesis bymeans of VEGFR-2 and integrins.

FIG. 20A-20E shows ear lymphatics after intravital infusion of colloidalcarbon in a control mouse and in mice injected at the indicatedintervals with Ad-PlGF or Ad-VEGF-A164. (FIG. 20a ) Control ear.Multiple injection sites (black blotches at top) were required to fillthe lymphatic network. Pattern of lymphatic filling in the ears of micepreviously injected, as indicated, with Ad-VEGF-A164. Giant lymphaticsare apparent as early as 3 days following injection (FIG. 20e ) andpersist through day 270. Kinetics of lymphatic filling in the ear of amouse 84 days following injection with Ad-VEGF-A164. Nagy J A, Vasile E,Peng D, J Exp Med, vol. 196, No 11, 1497-1506, 2002 [23].

For lymphangiogenesis, VEGF-C and -D are specific and more effectivethan VEGF-A as they induce sprouting and lymphatic proliferation. Satoet al. [153], incorporated herein by reference, VEGF A attractedmacrophages which in turn expressed VEGF-C and VEGF-D which induced newlymphatic formation. COX2 [154, 155], incorporated herein by reference,is up-regulated through the NFkB pathway induces VEGF-C production(Lactate initiates the induction of the NFkB inflammatory pathway [71,100, 144, 151, 154, 155].) Enholm et al. [156]transfected the VEGF-Cgene into a model showing its specificity for lymphangiogenesis.

Relative to the surrogate tumor blood vessels produced by VEGFA, Nagy[22, 23] stated “They arise from preexisting normal venules and arelarge, thin-walled, serpentine, pericyte-poor sinusoids that overexpress both of the VEGF-A receptor tyrosine kinases (VEGFR-1, VEGFR-2).MV (mother veins) then evolved into GMP and vascular malformations andalso into structurally normal capillaries by a process of transcapillarybridging.” Further Nagy said, “MV formed initially (1-5 days) and, fromabout 7 days, evolved into GMP (Glomeruloid bodies), vascularmalformations, and capillaries.” (FIG. 21, FIG. 22A-22C, and FIG. 23).It is interesting to note a similar time frame of the vessel formationas the 6.5 days in the Gimbrone experiment.

FIG. 21 shows angiogenic response to Ad-VEGF-A164 in the ears of nudemice at the indicated times and magnifications, from Nagy, J. A. et al.(2002) Cold Spring Harbor Symp Quant Biol 2002, 67:227-237 [157]

FIG. 22A-22C show vessels in ear skin at 18 hours after local injectionof adeno-vpf/vegf. FIG. 22a . Normal sized venule with slightly detachedpericyte (arrow). Note the extensive edema separating adjacent musclefibers. FIG. 22b . Evolving mother vessels illustrating striking vesselenlargement. EC (endothelial cell) activation (enlargement, prominentnucleoli) and pericytes (arrows) in various stages of detachment fromvessels. FIG. 22c . Higher power magnification captures three sectionsthrough mother vessels, thus illustrating highly irregular luminalsurfaces and EC (endothelial cell) bridging to form additional lumens(arrows) from Dvorak et al., Laboratory Investigation).

FIG. 23 shows a schematic diagram of mother vessel formation andevolution into daughter capillaries, vascular malformations andglomeruloid bodies, modified from Pettersson, A. et al. (2000) LabInvest, 80: 99-115 [158], incorporated herein by reference.

Fibroblast Growth Factor (bFGF or FGF2)

The FGF (fibroblast growth factor) family has two molecules, FGF2 (FGFb)and FGF1, although FGF2 is the more important and is typically referredto as FGF. FGF is produced by endothelial, cancer, stromal andinflammatory cells. As with VEGF, the local levels of FGF increase bythe same two mechanisms, i.e. release from the heparan sulfate matrixdue to the effects of waste products and the secondary production in thedelayed/maintenance stage by a variety of cells.

The primary action of FGF2 in the lowest concentration is thestimulation of lymphangiogenesis, while the secondary action isinduction of VEGF A, C, and D via the promoter element API. Chang [126]said, “Low-Dose FGF-2 Selectively Stimulates Lymphanglogenesis”, (FIG.24). “Although the effects of 12.5 ng FGF-2 pellet are mediated throughdifferent cytokines, i.e. VEGF-A, -C, and -D, the predominant result islymphangiogenesis.”

FIG. 24A-24I shows FGF-2 stimulates corneal lymphangiogenesis. FIG. 24A.In the traditional corneal assay, 80 ng of FGF2 (P) stimulates bloodvessel growth from the peripheral limbal vasculature (arrow). FIG. 24BThe traditional assay is viewed under fluorescent microscopy afterlabeling blood vessels yellow-green and lymphatic vessels red, (arrow).Sucralfate in the FGF2 pellet autofluoresces green. FIG. 24C. At theopposite end of the comes only lymphatic vessels sprout. Limbal vesselsin the control corneas. FIG. 24D. Lowering the dose of the FGF2 pelletto 12.5 ng (P) and moving it farther from the limbus results in lessangiogenesis, although lymphatic vessels still reach the pellet. FIG.24E. Corneal lymphatic vessels were morphologically different from bloodvessels. In additional corneal lymphatic vessels did not express CD34(FIG. 24F) or Tie 2(FIG. 24G, FIG. 24H) (arrow heads), but did expressVEGFR3, (I), from, Chang et al., Proceedings of the National Academy ofScience, 2004 [126].

Ephrin-2B, 4B

The ephrin family induced by hypoxia and HIF [159] affects theneovascularization processes [160, 161] after the early effects of VEGF.They are bidirectional markers. Ephrin-2B, an arterial marker, is theligand for the downstream Ephrin-4B (venous receptor). The Ephrin-4b isenriched in veins as the principle functional partner for ephrin-2B[152]. When Ephrin-4B levels are high they reverse signal the Ephrin-2Bto decrease arterial induction [161]. Hayashi [161], incorporated hereinby reference, reported that VEGF had a stimulatory effect on ephrinB2expression. Although this complicated feed forward/feedback processemploys both Ephrin-2B and arterial marker and Ephrin-4b a venousmarker, functionally the vascular development is based on the venoussystem. Hayashi et al. [161] stated, “An Ephrin-2B-rich environment wasshown to induce neovascularization mainly through venous angiogenesis.”

Angiopoietin

Angiopoietin 1 induces maturation of the newly formed vessels byincreasing pericyte coverage and restoration of the basement membrane toits normal structure. Angiopoietin 2 blocks the angiogenic functions ofAngiopoietin 1, Yancopoulos, G. D. et al. (2000) [162], incorporatedherein by reference. Their receptor site, TIE-2 observed in early animalmodels was believed to be an arterial marker [146] but modernspecification data confirms it is venous [119, 147, 162]. The mostrecent and definitive report was by Swift in Circulation Research (2009)[119] and emanating from the NIH Laboratory for Molecular Genetics.

Other Growth Factors Related to VEGF and FGF

There are many other angiogenic factors, which will only be discussedbriefly for the sake of brevity. Most of these act or are formed by theactions of VEGF and FGF. These include platelet derived growth factor(PDGF), epidermal growth factor (EGF), IL-1 and others. Prostaglandinspresensitize vessels to the effects of VEGF.

VII. Histopathology of Implanted Tumor Shows the First Vessel Ingrowthto be Venous Loops from Existing Veins

Patan et al. [163], incorporated herein by reference, implanted humancolon carcinoma into the ovarian pedicle of nude mice and permittedgrowth for 21 days. At 3,7,14, and 21 days, the tumors were harvested,and microscopic serial sections made, ie. as many as 3500 serialhistologic sections. At approximately seven days, they noted that vesselmorphogenesis occurred in the small veins surrounded by tumoraggregates. They also noted venous loop formation, which began fromlarger veins in different tissue sites. The vessels were divided byintussceptive microvascular growth in the lumens as well as bysegmentation.

Patan [163] stated, “Reconstruction of 3500 histological serial sectionsdemonstrated that a new vascular network composed of venous-venous loopsof varying sizes grows inside the tumor from the wall of the adjacentmain vein.” It should be noted that the source did not note any arterialchanges in these dissections (FIG. 25). Dr. Patan verified that she sawno arterial morphogenesis in the study sections.

FIG. 25 shows an overview of the dilated main ovarian vein located closeto the tumor margin (at the right) and near the ovarian artery (at theleft). The venous lumen is divided by folds and ITSs, intussuceptivechanges, arrows. A-L, from Patan et al., Circ. Res 2001, 89; 732-739[163].

Vasculogenesis Models Document Sequential Development ofLymphangiogenesis, Phlebogenesis and Arteriogenesis Consistent withALPHA

The metabolic and signaling data discussed relative to ALPHA correlateswell with observations from published animal models [109, 149, 150, 152,164], incorporated herein by reference. In the medical literature,reports on blood vessel vasculogenesis were studied earlier thanlymphangiogenesis because visualization of lymphatics in models wasdifficult because of their transparency. With the development ofspecific biomarkers, a more comprehensive appreciation of vasculogenesisis possible by collating the recent reports on lymphangiogenesis withearlier reports on blood vessel angiogenesis.

Lymphangiogenesis

The mechanisms and processes of lymphangiogenesis were recently reportedby Eitchen et al. [109] using a de nova squamous cell cancer murinemodel. With these mice, skin lesions evolve over six months fromdysplastic sites into squamous cell in situ and subsequently locallyinvasive squamous cell tumors. Eitchen et al. [109] quantitated theproliferation rate of lymphatic endothelial cells and blood vesselsendothelial cells (it is not explained why stains were not use stains todifferentiate veins and arteries).

FIG. 26 show the rate of lymphatic endothelial cell proliferation isgreater than that of vascular endothelial cells during the transitioninto the malignant form (SCC-I-P, SCC-I-C, SCC-II-P). VEC and LECproliferation in premalignant and carcinoma tissue. Quantitativeanalysis of proliferating VECs and LECs in—LM, premalignant andcarcinoma tissue. Proliferating LECs were identified in the peripheryand center of well-differentiated grade 1 SCCs (SCC-1) but limited toperiphery of less-differentiated grade 2 SCCs. Absence of open lumenlymphatic vessels SCC-II centers precluded analysis of LECs in thatlocale. *, P<0.05, two-tailed unpaired nonparametric Mann-Whitney U testDashed line, basement membrane. Blue staining, SYTO62-nuclearcounterstain, Cancer Res, 2007; 67(11): 5211-20 [109].

The sequential vasculogenic changes observed Eitchen et al. confirmedthat morphologic changes of lymphatics occur before blood vesselchanges, FIG. 26. During the premalignant state, the proliferation rateof the lymphatic endothelial cells was less than the blood vessel rate,but increased dramatically when squamous cell carcinoma in situdeveloped. Lymphatics were abundant centrally and peripherally. As thesquamous cell became less differentiated the center portion was devoidof open lumen lymphatics, but the peripheral areas had increasedlymphatics. With blood vessel endothelial cells, they were present inboth the center and the periphery in the less differentiated tumors. Thephenotypic changes differed between blood vessels and lymphatics. Thelymphatic vessels increased only in size and not density, while themorphogenic changes caused by increased diameter and number/density.

The same processes described by Eichten et al. [109] were manifested inthe transfected VEGF/VPF DNA model described by Nagy and Dvorak [20-23]and shown in FIG. 18. They observed the earliest lymphatic changesinduced by VEGF/VPF were dilatation of the host lymphatics. Thesechanges occurred at 1-3 days, before there were subsequent changes inthe veins and then arteries.

Eichten et al. [109] elegantly expressed the dynamic relationshipbetween blood vessels and lymphatics. They noted that as the bloodvessels become more permeable and leak into extracellular space duringtransition between the premalignant and malignant phases the excesstissue fluids are efficiently drained by the enlarged lympaticsbalancing the fluid dynamics. As discussed earlier, cancer producesexcess lactate in the extracellular space which stimulates hyaluronanforming lymphatics, which modulate amount of lactate laden extracellular fluid [88, 108, 165, 166], incorporated herein by reference.

Blood Vessel Anglogenesis: Veins and Arteries

While there have been many vasculogenesis reports, most were publishedbefore the modern data was available. Rather than attempting tosummarize than all and collate than with ALPHA, the discussion is framedaround several reports by recognized investigators from only a few ofthe high quality journals, i.e. Journal of the National Cancer Institute[164], Proceedings of the National Academy [72], Cancer Research [150].

The primary report serving as the central discussion focus is by Li etal. [164] in the Journal of the National Cancer Institute, titled,“Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via SkinWindow Chambers in Rodent Models.” The uniqueness of this report is thatthey made numerous observations which were not understood at the timebut in the light of modern data are completely consistent with the ALPHAconcept.

The specifics of their experiment were as follows. A transparent windowmodel in mice created and 20-50 cells were injected into thesubcutaneous space. The cells were transfected with a green fluorescentprotein so they were clearly visible during the morphologic angiogenicchanges in the tissues. The tumor was observed for up to 4 weeks.

FIG. 27 shows the growth of a tumor from single 4T1 cells in a BALB/cmouse window chamber. Approximately 20 cells were injected in a BALB/cmouse window chamber and their growth followed serially after theinitial implantation (white arrows on Day 1 indicate reference vesselsseen on all images) which show references visible Red arrow in the day-2panel indicates an elongated cell. Red arrows in the day-6 panelindicate dilated host vessels compared with the day-4 panel. Arrows inthe day-8 panel indicate new microvessels. Pink arrows point to tumor(localized in the marked circle)-associated microvessels, and red arrowsbeneath the circled area point to dilated and/or tumor-inducedvasculature outside the tumor. Size bars in the day-1 to day-8 panelsrepresent 200 μm; size bar in the day-20 panel represents 500 μm, fromJ. Nat. Cancer Institute, 2000; 92(2):143-7 [164].

Li et al. [164] stated three phases for angiogenesis, FIG. 27: “1) theinitial orchestration of tumor angiogenesis involved migration of tumorcells toward existing vasculature before neovascularization, Day 1-4. 2)Changes in surrounding microvessel structure, such as vasodilation andincreased tortuosity, were seen at the approximately 60- to 80-cellstage of tumor growth, day 6-8.3) Clear demonstration of new vesselformation was seen at the approximately 100- to 300-cell stage of tumorgrowth.”

Their observations that angiogenic changes occurred when the tumor cellmasses were so small inferred that the tumor was not hypoxic because thecell number did not exceed 10⁵ cells or the overall size of 1-2 mm. Theystated “Angiogenesis induced by tumor cells after implantation in thehost begins at a very early stage, i.e., when the tumor mass containsroughly 100-300 cells.” The variance with other sources discussinghypoxia and tumor size was noted but no cogent explanation was offered.As will be discussed later other sources [150, 167] have specificallystated this.

Their observation about, “Identification of chemotactic signals thatinitiate tumor cell migration toward the existing vasculature” indicatesthe activity of acidic lactate during transformation in themicroenvironment. Although the causation of cell mobility and spindleconfiguration was not known at that time, it has since been proven thatthese changes can only occur by the lactate induction of hyaluronan inthe tissues [86, 165, 166, 168, 169], incorporated herein by reference.Lactate is the only molecule which up-regulates the production ofhyaluronan from fibroblasts, endothelial cells, and cancer cells [86,165, 168-170] which is essential for motion and spindle shape. Asmentioned earlier, hyaluronan produces these changes by attaching tospecific hyaluronan receptor RHAMM on the cells membranes [86, 170],incorporated herein by reference. This attachment induces changes in thecytoskeleton, motogenic genes and mitotic spindle.

With transformation of the microenvironment, two processes whichincrease vascular growth mediators occur. VEGF and FGF have been foundto be the essential growth mediators for the initial incipientangiogenic burst [149]. The low pH and lactate initiate early release ofFGF and VEGF, which is stored dormantly [121, 122]. As previouslydiscussed, dilatation of host vessels observed by Li et al. at Day 4-6,FIG. 27, is the first blood vessel change in blood vessels (afterlymphatics) caused by VEGF [22, 23]. The second phase,delayed/maintenance neoangiogenesis observed at Day 8, is due toincreased production of diverse vascular growth mediators from multiplepathways including hypoxia induced HIF, TGFb, NFkB and other signalingpathways [71, 85, 96, 100, 171-173], incorporated herein by reference,see Indracolla in FIG. 28.

FIG. 28 shows a summary of the microenvironment. The tumor massenvironment is composed of heterogeneous mixture of stromal cells (suchas fibroblasts, endothelial cells, and immune cells such as macrophagesand ECM (extracellular matrix) components). Transformation of themicroenvironment occurs with the activation of the metalloproteaseswhich occurs as result of lactate effect on TGF b [68] and onmacrophages with the release of IL-23/17 [72], and FGF2. Lactate inducedMCT lactate transporters also activate metalloproteses in conjunctionwith lactate induced hyaluronan/CD147, and caveolin-1 [69] and FGF.IL-17 enhances the vascular growth effects of FGF2 and VEGF. Lactateinduces the NFkB inflammatory pathway which increases various cytokinesand COX 1 and COX-2 and anti apoptotic pathways [71]. The resultingprostaglandins enhance vasculogenesis. The tumor mass uses these variouscell types to secrete cytokines, growth factors such as VEGF and TGF-b(transforming growth factor b), and matrix degrading proteins (MMP's) tocreate a prometastatic niche that supports the tumor during invasion,angiogenesis, and extravasatin. In addition, integrins and theirreceptors mediate cellular attachment and communication, from Alphonsoand Alahari, Neoplasia, p1264-71, December 2009 [174], incorporatedherein by reference.

With recognition of the importance of transformation of themicroenvironment it is relevant to note the role of acidic lactate ininducing the transformation and the effects on the metalloproteases,certain signaling pathways, and different cellular elements.

Angiogenesis Produced by Acidic Lactate Effects on Microenvironment

The merits of the ALPHA concept for angiogenesis are definitelysupported by recent data reported by Indracollo et al. in theProceedings of the National Academy [149]. In their report they notedthat there were two distinct phases of angiogenesis, an early and adelayed/maintenance phase. The first phase was supported solely by FGFand VEGF while the later phase was supported by numerous other vasculargrowth factors, FIG. 29A-29B.

The other diverse vascular growth factors for the delayed/maintenanceangiogenesis included COX2, Angiopoietin 1, IL-6, IL-8, IL-15 andothers. The total dependence of the first stage on FGF and VEGF and theinteraction and synergy of the many factors for the later phase has beenemphasized by numerous sources [175-178], all incorporated herein byreference.

FIG. 29A-29B shows graphs demonstrating the effects of bFGF and VEGF onMOLT-3 tumor growth. FIG. 29A shows MOLT cells with matrigel (MG) anddifferent vascular mediators. MG-MOLT3+bFGF pellets showedearly/incipient and delayed/maintenance angiogenesis and growth.MG-MOLT3+KS (Kaposi Sarcoma)—IMMirr shows similar early and delayedgrowth. Indraccolo et al. state, “The phenomenon depends mainly on theinfluence of KS cells on the host microenvironment” [149]. Delayedgrowth of MG-MOLT3+VEGF produced delayed growth and angiogenesis.Without Kaposi cell sarcoma co injection the two phases early/incipientand late/delayed did not occur.

FIG. 29B shows the growth curves of MOLT3 cells which were transfectedwith retroviral vectors for bFGF and VEGF. MOLT3 cells that weretransfected whether irradiated or not were capable of sustainingprogressive growth. The delay in onset of growth was due to delay inmediator production. The cells not irradiated (MOLT3-VEGF andMOLT3-bFGF) grew earlier than the irradiated ones (MOLT3-MOLT-3VEGFirr,MOLT3-MOLT-3bFGF in). The MOLT3 GFP labeled with fluorescence did notgrow because no growth factors were provided. As an aside it isinteresting to note the animals were not submitted to hypoxia so it islikely that the tissues were at least initially normoxic.

Finally the most important conclusion by Indracolla et al. [149] is thatthe initial angiogenic burst which interrupted dormancy was not due tothe tumor cells themselves but their effects on the microenvironment.This was definitively emphasized by direct statements by the sources.Indracolla titled the report, “Interruption of tumor dormancy by atransient angiogenic burst within the tumor microenvironment.”Indracolla et al. further stated that the angiogenic “phenomenonobserved depends mainly on the effect of the KS (Kaposi Sarcoma) cellson the host microenvironment.” They also stated “A transient change inthe microenvironment, such as that provided by local inflammation, wouldsuffice for tumor cells with even low angiogenic potential to escapefrom dormancy and give rise to progressively growing lesions.” It is areasonable conclusion that acidic lactate may be the prime cause of suchchanges.

Oxygenation Levels: Normoxic State of Incipient Angiogenesis and HypoxicState of Delayed Anglogenesis

In addition to the inferences by Li et al. and others a verysophisticated study by Cao et al. [150] confirmed the differentoxygenation levels of the two stages of angiogenesis. Their findingswere clearly indicated by the title, “Observation of Incipient TumorAngiogenesis That Is Independent of Hypoxia and Hypoxia InducibleFactor-1 Activation.”

Their experimental design was simple, elegant, and sophisticated using amurine transparent widow model, as follows. They used “geneticallyengineered HCT116 human colon carcinoma cells and 4T1 mouse mammarycarcinoma cells with constitutively expressed red fluorescence proteinas a tumor marker and green fluorescence protein (GFP) as a reporter forhypoxia and HIF-1 activation.”, see FIG. 30A-30I.

FIG. 30A-30I shows suppression of hypoxic response by selectivelykilling hypoxic cells does not delay incipient tumor angiogenesis. FIG.30A shows a representative window chamber images of a saline-treatedHCT116 tumor revealing the incipient angiogenesis (Day 2; black arrows)before the hypoxic response (Day 3; green arrow). Endothelial cords andsprouts surrounding the hypoxic region (Day 3; black arrows) developedinto a vascular plexus (Day 4; white dashed circle). Bar, 0.3 mm. FIG.30B shows a representative window chamber images of atirapazamine-treated HCT116 tumor revealing incipient angiogenesis (Day2; black arrows) and its development into a vascular plexus (Day 10;white field) in the absence of hypoxic response (no GFP fluorescence).Bar, 0.3 mm. FIG. 30C shows probabilities of time required for theinitial hypoxic response in tirapazamine versus saline-treated HCT116window chamber tumors. Tirapazamine treatment significantly delayed theinitial hypoxic response when compared with saline treatment (mediantime: 9.5 days in the tirapazamine-treated group versus 3.5 days in thesaline-treated group; Kaplan-Meier analysis, n=8, log-rank test,P<0.001). FIG. 30D shows probabilities of times required for onset ofincipient angiogenesis in tirapazamine versus saline-treated HCT116window chamber tumors. No significant difference was found betweentirapazamine treatment and saline treatment (Kaplan-Meier analysis, n=8,log-rank test, P=0.33). FIG. 30E, representative window chamber imagesof a saline-treated 4T1 tumor revealing incipient angiogenesis (Day 2;black arrows) before the hypoxic response (Day 4; green arrow). Bar, 0.3mm. FIG. 30F, representative window chamber images of atirapazamine-treated 4T1 tumor revealing incipient angiogenesis (Day 3;black arrows) before the hypoxic response (Day 7; green arrow). Bar, 0.3mm. FIG. 30G, probabilities of the time required for the initial hypoxicresponse in tirapazamine versus saline-treated 4T1 window chambertumors. Tirapazamine treatment significantly delayed the initial hypoxicresponse when compared with saline treatment (median time: 5.5 days inthe tirapazamine-treated group versus 4 days in the saline-treatedgroup; Kaplan-Meier analysis, n=8,log-rank P<0.05). FIG. 30H,probabilities of time required for incipient angiogenesis intirapazamine versus saline-treated 4T1 window chamber tumors. Nosignificant difference was found between tirapazamine and salinetreatment (Kaplan-Meier analysis, n=8, log-rank P=0.66). FIG. 30I, VEGFlevels in the culture media of HCT116 and 4T1 cells treated with hypoxiaversus normoxia. Hypoxia significantly stimulates VEGF secretion (n=6, ttest, *P<0.001). Columns, mean; bars, SE. Notably, both cell linessecrete low levels of VEGF under normoxic conditions, from Cao et at,Cancer Research, 2004 [150].

The reference stated, “Mouse dorsal skin-fold window chambers showedthat incipient angiogenesis preceded a detectable level of hypoxia. Thedetectable levels of hypoxia were spatially and temporally related withmore intensive secondary angiogenesis following the initial onset of newvessel formation. Selective killing of hypoxic cells by tirapazamineefficiently eliminated or delayed the detection of hypoxic cells, but itdid not significantly delay the onset of incipient angiogenesis”, FIG.30A-30I. Other sources [117, 167] have also confirmed angiogenesis maybe initiated without hypoxia or HIF. Hendriksen [167] studiedglioblastoma implanted tumors in a murine model and noted no hypoxia orHIF1a in small tumors. He stated, “in the tumors of one to fourmillimeters little or no hypoxia was detectable together with anincreasing vascular development.”

Summary Observations Supporting ALPHA

A brief, simple summary of their observations and relevance to ALPLHA isas follows. Cell movement and spindle shape of the tumor cells occurredat Day 1-4, which indicated the presence of low pH and lactate in themicroenvironment. The presence of acidic lactate indicatedtransformation of the microenvironment which increases vascularmediators by two distinct pathways, one is release of dormantly storedangiogenic growth factors FGF and VEGF and the second is production ofadditional growth factors by other pathways (NFkB). Two distinct stagesof angiogenesis were observed by Li et al. [164], early incipient at Day4-6 and a delayed neoangiogenesis at Day 8. The early phase consisted ofdilatation and enlargement of co-opted host vessels, Day 6, is known tobe caused by the action of VEGF. This early phase was inferred by Li etal. [164] to be normoxic by virtue of the small tumor size and proven tobe normoxic by others. In normoxia, release of VEGF from heparan matrixis dependent only upon acidic lactate not the oxygenation level. Thedelayed neoangiogenesis, which occurred at Day 8, is due to the effectsof numerous vascular growth factors, likely by hypoxia and acidiclactate (see below oxygenation section). As noted above reports by Caoand Indracolla support the two critical premises of ALPHA that the earlyincipient angiogenesis is normoxic and that the vasculogenesis processoccurs because of the effects of tumor on the microenvironment.

Analysis Conclusions

In a broad sense, the traditional angiogenesis theory has producedremarkable benefits to healthcare in that it has stimulated extensiveresearch into molecular signaling pathways. However, it has notspecifically fulfilled its promise to revolutionize the diagnosis andtreatment of cancer, indicating that a new paradigm is needed as arecancer treatments that conform to this new paradigm Major deficienciesand numerous inconsistencies in the application of the traditionaltheory have become apparent with the premise that hypoxia drivesangiogenesis and that arterial growth and oxygenation drives tumorgrowth. The traditional theory cannot explain why anti-VEGF drugs do notwork as a single agent. Current theory does not explain how angiogenesiscan occur in normoxic or hyperbaric situations. Normalization ofoxygenation in cancer patients does not increase cancer recurrence.Furthermore, successful modern imaging perfusion methods depend uponvenous, not arterial, attributes. Review and reinterpretation of theoriginal Gimbrone and Folkman study [4] supports the ALPHA concept. Ifone considers the abundant data in many fields it can be used toformulate the proposed A3L2PHA concept which provides an alternateperspective on vasculogcnesis.

Glycolysis is preferred by cancer because of numerous reasons. First itproduces abundant energy but with large amounts of lactate. It is notintended that embodiments of the invention be limited to any particularmechanism; however, it is believed that moderate acidic lactate levelsenhance cancerous process but excessive levels causes changes supportingdormancy, i.e. lower metabolism, reduced protein synthesis, reducedmitosis and proliferation, and lack of apoptosis). It is not intendedthat embodiments of the invention be limited to any particularmechanism; however, it is believed that removal or reduction of lactate(by change of culture medium or increased transport by lymphovenousdrainage) restores tumor growth teleologically,

The needs of cancer and normal cells are completely different, onedepends upon glucose while the other depends upon oxygen and glucose.Teleologically, why would an organism preferring glycolysis notrequiring oxygen want to grow arteries? It is more logical that it wouldrequire lymphovenous drainage to modulate and optimize the appropriatelevel of lactate.

It is not intended that embodiments of the invention be limited to anyparticular mechanism; however, it is believed that low pH and elevatedlactate have well defined signaling pathways which induce most of thevascular mediators (FGF, VEGF, ephrin, PDGF, etc). Embryologic models,animal dissection studies and immunopathologic for vascularspecification have shown that the mechanistic site of the vasculargrowth mediators sequentially occur on the lymphatics, veins, andfinally arteries.

Modern angiogenesis models correlate well with the extensive basicscience data. T It is not intended that embodiments of the invention belimited to any particular mechanism; however, it is believed that therecognized stages of angiogenesis (transformation of themicroenvironment, early incipient angiogenesis, delayed maintenanceangiogenesis can all be explained by the effects of low pH and elevatedlactate. Modern models show that angiogenesis is not a single triggerstep, but occurs in two stages or phases, with the first likely beingnormoxic. It is not intended that embodiments of the invention belimited to any particular mechanism; however, it is believed that thekilling of hypoxic cells does not prevent incipient early angiogenesis.These models confirm the initial phase is normoxic and the angiogenicburst, which interrupts tumor dormancy results from tumor effects on themicroenvironment. The most recent models show that the initial releaseof FGF and VEGF required for incipient angiogenesis occurs fromtransformation of the microenvironment induced by acidic lactate. It isnot intended that embodiments of the invention be limited to anyparticular mechanism; however, it is believed that the laterneoangiogenic phase occurs because of hypoxia but also likely from thediverse effects of acidic lactate both locally and as an induction agentfor inflammatory pathways and diverse angiogenic growth factors.Correlation of the many models shows that vasculogenesis sequentiallydevelops lymphangiogenesis, phlebogenesis and finally arteriogenesis.

The role of the ALPHA paradigm has yet to be determined but it seemscomplementary, synergistic and perhaps dominant to the traditionalhypoxic vasculogenesis concept Cancer uses both the aerobic and theglycolytic pathways, which have different teleologic needs (aerobicrequires oxygen and glycolysis requires efficient waste drainage).Depending upon the oxygen state, normoxia or hypoxia, either thetraditional or the ALPHA vasculogenesis paradigm is more important thanthe traditional paradigm. ALPHA is well founded in the literature avigorous vetting in the scientific community is warranted. It is notintended that embodiments of the invention be limited to any particularmechanism; however, it is believed that ALPHA paradigm's role is likelycomplementary to the hypoxic process but perhaps dominant because itoperates at all oxygenation levels. It is not intended that embodimentsof the invention be limited to any particular mechanism; however, it isbelieved that ALPHA can initiate and support angiogenesis in normoxiaand supplement hypoxic angiogenic effects with increased production ofacidic lactate. Effective anti angiogenic treatment will requiretreatment of both major vasculogenesis pathways.

ALPHA emphasizes the importance of low pH and elevated lactate for theinduction of vasculogenesis (lymphatics, veins, and arteries) and thegrowth and malignant spread of cancer. Interruption or diminution of theacidic lactate by treatment will reduce or eliminate vasculogenesiscaused by this waste product and also reduce or eliminate the manyadvantages of elevated lactate on the cancerous processes discussedherein, i.e. adaptive selective environment, facilitation of cancer cellmutation and proliferation, induction of hyaluronan which enhances cellmigration and metastases, induction of NFkB pathways known to upregulateanti-apoptotic pathways, transform macrophages and fibroblasts to tumorforms, impairment of the local immune system, induction of cytokines andCOX2 known to induce and support cancer, and others.

The proposed treatment with CAIX,CAXII, and aquaporin blockage will:1)reduce and block the ALPHA vasculogenesis mechanism 2) reduceintracellular pH in cancer cells causing damage or death 3) the inducedlower intracellular pH will block glycolysis (there by reduceextracellular and intracellular lactate) due to end product inhibitionas well as inhibit phosphofrutose kinase by the decreased pH which isthe dominant regulatory step of glycolysis 4)impair the metabolon ofCAIX and MCT1/MCT4 which are codependent and spatially correlated(pearson correlation of Grillon, E. at al. (2011)[179])

New Methods of Treating Hypoxic Cancer

Selvakumaran, M. et al. (2008) [180], incorporated herein by reference,discloses that the addition of the anti-vascular endothelial growthfactor (anti-VEGF) monoclonal antibody bevacizumab to a chemotherapyregimen resulted in improved response rates and survival in patientswith advanced disease. Selvakumaran, M. et al. determined thatbevacizumab treatment is an effective inducer of a hypoxic environment,but the resulting cell death and tumor shrinkage is determined by thesusceptibility of the tumor to apoptosis. The induction of apoptosis byhypoxia may contribute to the benefits of such treatment in the clinicalsetting. In many cases, hypoxia induction does not induce apoptosis,such cases present a significant challenge in the treatment of cancer.

It is not intended that embodiments of the invention be limited to anyparticular mechanism; however, it is believed that cancers preferglycolytic metabolism, requiring only glucose and not oxygen, whichmakes ample ATP energy but also creates large amounts of lactate and lowpH. Although it is not necessary to understand the mechanism of aninvention, it is believed that depending upon the concentration levelsthese waste products may provide specific benefits to cancer, causetumor dormancy, and transform the microenvironment. It is not intendedthat embodiments of the invention be limited to any particularmechanism; however, it is believed that stabilizing the macroenvironmentof hypoxic cancer tissues can significantly contribute to the treatmentof said cancer. It is not intended that embodiments of the invention belimited to any particular mechanism; however, it is believed that in asmuch angiogenesis follows transformation and interrupts tumor dormancy,thus promoting cancer growth, complementation of a treatment tostabilize the microenvironment of cancer with an angiogenesis inhibitorscould be an effective treatment for various cancers. It is not intendedthat embodiments of the invention be limited to any particularmechanism; however, it is believed that new evidence suggests thatvascular changes occur sequentially in the lymphatics, veins, andlastly, the arteries (not first, as previously believed).

It is not intended that embodiments of the invention be limited to anyparticular mechanism; however, it is believed that the use of carbonicanhydrase 9 or carbonic anhydrase 12 inhibitors, such as bumetanide,could be used to destabilize the pH homeostasis of the cancer tissuesinducing severe or lethal damage selectively to cancer cells which arerich in CAIX and XII, as compared to normal tissue. Further, withinhibition of CAIX and CAXII, the cancer cell internal pH will decreaseincreasing acidity. Basic biochemistry of glycolysis indicates the mainregulatory enzyme/molecule phosphofiuctokinses is inhibited by low pHreducing or stopping glycolysis. With reduced or cessation ofglycolysis, reduce lactate levels will deprive the cancer of themodulated benefits including anti-apoptosis, selective adaptiveenvironment, “stemcell “properties permitting mutation. Butamideblocking of aquaporin will prevent oncotic equilibration and therebyinduce additional hyperosmotic damage. With restoration of the normalcellular microenvironment will enable effective treatment of cancer withother chemotherapeutic agents, including, but not limited toangiogenesis inhibitors. In one embodiment, the invention relates to amethod of treating cancer comprising targeted delivery of carbonicanhydrase inhibitor, such as bumetanide, to cancerous tissues, lesions,or tumors. In one embodiment, the invention relates to the delivery of acarbonic anhydrase inhibitor, such as bumetanide, to cancerous tissuesin an effective amount necessary to prevent hypoxic conditions orreverse hypoxic conditions. In one embodiment, prevention of hypoxicconditions will effectively treat said cancer. In some embodiments,various thiazide diuretics, such as bumetanide, can be consideredcarbonic anhydrase inhibitor.

In one embodiment, the invention relates to a method of treating cancercomprising administering to a patient in need of therapy an effectiveamount of low dose, frequently administered combination of a carbonicanhydrase inhibitor and an angiogenesis inhibitor. In one embodiment anangiogenesis inhibitor includes tumor-vascular disrupting agentsdescribed by Siemann (2011) [181], incorporated herein by reference. Inone embodiment, said angiogenesis inhibitor is selected from the groupconsisting of ZD6474, ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab,mv833, anti-FLT-1 ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055,SU11248, and mixtures thereof. In one embodiment, said angiogenesisinhibitor is bevacizumab. In one embodiment, said carbonic anhydraseinhibitor is bumetanide. In one embodiment, said carbonic anhydraseinhibitor is a carbonic anhydrase 9 and carbonic anhydrase 12 inhibitor.In one embodiment, the treatment results in one or more of clinicalbenefit remission, an increased quality of life or prolongation ofsurvival of the patient. In one embodiment, said treatment results inthe shrinkage of a tumor or prolonged stability of the cancer. In oneembodiment, said treatment reduces metastases of said cancer.

In one embodiment, the invention relates to a pharmaceutical compositioncomprising an effective amount of a combination of a carbonic anhydraseinhibitor and an angiogenesis inhibitor. In one embodiment, saidangiogenesis inhibitor is selected from the group consisting of ZD6474,ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab, mv833,anti-FLT-1ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248, andmixtures thereof. In one embodiment, said angiogenesis inhibitor isbevacizumab. In one embodiment, said carbonic anhydrase inhibitor isbumetanide. In one embodiment the invention relates to the compositiondescribed above adapted for parenteral administration. In one embodimentthe invention relates to the composition described above adapted forintravenous administration.

In one embodiment the invention relates to a method for treating apatient with cancer, wherein said cancer is unresponsive to traditionaltherapy, said method comprising administering to said patient acombination of a carbonic anhydrase inhibitor and an angiogenesisinhibitor in amounts effective to provide a clinical benefit remission,an increased quality of life or prolongation of survival of the patient.In one embodiment, said cancer is hypoxic cancer. In one embodiment,said treatment results in the shrinkage of a tumor or prolongedstability of the cancer. In one embodiment, said method results in acomplete remission of said cancer. In one embodiment an angiogenesisinhibitor includes tumor-vascular disrupting agents described by Siemann(2011) [181], incorporated herein by reference. In one embodiment, saidangiogenesis inhibitor is bevacizumab. In one embodiment, said carbonicanhydrase inhibitor is bumetanide.

In one embodiment, the invention relates to the treatment of hypoxiccancer. In one embodiment, treatment of hypoxic cancer includes targetedbloodstream injection of a carbonic anhydrase inhibitor, such asbumetanide. In one embodiment, treatment comprises catheterization ofthe hepatic artery. In one embodiment, treatment comprises occludingarteries with the treatment of bumetanide. In one embodiment, treatmentcomprises embilization. In one embodiment, treatment comprisesembilization with polymers embedded with carbonic anhydrase inhibitors.In one embodiment, said carbonic anhydrase inhibitors includes acarbonic anhydrase 9 or 12 inhibitor, such as bumetanide. In oneembodiment, said polymers embedded with carbonic anhydrase inhibitorsslowly release bumetanide. Some non-limiting example of such polymersincludes: U.S. Pat. No. 5,384,333 [182], U.S. Pat. No. 5,302,397 [183],and U.S. Pat. No. 5,626,877 [184] (all herein incorporated byreference). In one embodiment, said polymers embedded with carbonicanhydrase inhibitors includes a bumetanide-loaded polymeric implant forthe treatment of solid tumors, for example using a system described byWadee et al. (2011) [185]. In one embodiment, said polymers embeddedwith carbonic anhydrase inhibitors, such as bumetanide, releasebumetanide over a long period of time. In one embodiment, slow deliveryof bumetanide is from the extended release formulation. In oneembodiment, said polymers embedded with carbonic anhydrase inhibitorsare introduced in a single step. In one embodiment, said polymersembedded with carbonic anhydrase inhibitors are introduced several timesover the course of treatment. In one embodiment, said treatmentbumetanide is given intravenously in combination with arteryembilization with polymers embedded with carbonic anhydrase inhibitors.

An important permutation will be a slow release form of bumetanide, inone embodiment, over 8-12 hours. This will be important for continuingoral therapy because IV treatment may be necessary One reference thatdescribes various slow release forms of bumetanide is Hamed, E. A. M.(2002) Application and Evaluation of Extended Release Technology toLoop, Diuretics Doctoral Thesis [186], herein incorporated by reference.Other types of carbonic anhydrase inhibitors are know to be used in slowrelease form, such as those described in U.S. Pat. No. 5,095,026 [187],herein incorporated by reference. A slow release pill form of bumetanideand as well any other CAIX, CAXII inhibitor on the market are consideredforms of carbonic anhydrase therapy. The action of such drugs is quiterapid and therefore one embodiment involves slow release formulas ofsuch carbonic anhydrase inhibitors, such as bumetanide. In oneembodiment the invention relates to both acute and long term treatmentwith a slow release carbonic anhydrase inhibitor to chronically suppressCAIX and CAXII.

In one embodiment, the invention contemplates methods and compositionsfor the treatment of cancer. In one embodiment, the invention relates tothe treatment of hypoxic cancer. In one embodiment, said cancercomprises well defined tumors. In one embodiment, said treatmentinvolves thermal ablation of arteries or other blood vessels supplyingblood to well defined tumors in combination with treatment withbumetanide. In one embodiment, said treatment of said cancer withthermal ablation is proceeded with bumetanide treatment. In oneembodiment, a catheter is introduced to the hepatic artery for thethermal ablation and delivery of a carbonic anhydrease inhibitor, suchas bumetanide, for treatment to occlude arteries of interest supplyingblood to said cancer. In one embodiment, thermal ablation includes, butis not limited to radiofrequency thermal ablation (RFA), cryoablation,microwave ablation, laser ablation, and ultrasound ablation. In oneembodiment, treatment comprises additional treatment with anangiogenesis inhibitor. In one embodiment an angiogenesis inhibitorincludes tumor-vascular disrupting agents described by Siemann (2011)[181], incorporated herein by reference. In one embodiment, saidangiogenesis inhibitor is selected from the group consisting of ZD6474,ZD 6126, AZD2171, SU6668 and SU5416, bevacizumab, mv833, anti-FLT-1ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248, andmixtures thereof.

In one embodiment, said treatment involves electroporation with a nanoknife system of arteries or other blood vessels supplying blood totumors or the cancer cells themselves in combination with treatment withbumetanide. In one embodiment, said treatment of said cancer withelectroporation is preceeded with bumetanide treatment.

In one embodiment, the invention relates to a composition for thetreatment of cancer in a subject. The composition comprises anangiogensis inhibitor or pharmaceutically acceptable salt or prodrugthereof and a carbonic anhydrase inhibitor or pharmaceuticallyacceptable salt or prodrug thereof. In one embodiment, said antiogenesisinhibitor is bevacizumab. In one embodiment, said carbonic anhydraseinhibitor is a carbonic anhydrase 9 or carbonic anhydrase 12 inhibitor.In one embodiment, said carbonic anhydrase inhibitor is bumetanide. Inanother aspect, the method comprises administering to the subject aangiogensis inhibitor or pharmaceutically acceptable salt or prodrugthereof and a carbonic anhydrase inhibitor or pharmaceuticallyacceptable salt or prodrug thereof.

Although the invention has been described with reference to thesepreferred embodiments, other embodiments can achieve the same results.Variations and modifications of the present invention will be obvious tothose skilled in the art and it is intended to cover in the appendedclaims all such modifications and equivalents. The entire disclosures ofall applications, patents, and publications cited above, and of thecorresponding application are hereby incorporated by reference.

Thus, specific compositions and methods of targeted treatment ofanerobic cancer have been disclosed. It should be apparent, however, tothose skilled in the art that many more modifications besides thosealready described are possible without departing from the inventiveconcepts herein. The inventive subject matter, therefore, is not to berestricted except in the spirit of the disclosure. Moreover, ininterpreting the disclosure, all terms should be interpreted in thebroadest possible manner consistent with the context. In particular, theterms “comprises” and “comprising” should be interpreted as referring toelements, components, or steps in a non-exclusive manner, indicatingthat the referenced elements, components, or steps may be present, orutilized, or combined with other elements, components, or steps that arenot expressly referenced.

All publications mentioned herein are incorporated herein by referenceto disclose and describe the methods and/or materials in connection withwhich the publications are cited. The publications discussed herein areprovided solely for their disclosure prior to the filing date of thepresent application. Nothing herein is to be construed as an admissionthat the present invention is not entitled to antedate such publicationby virtue of prior invention. Further, the dates of publication providedmay be different from the actual publication dates, which may need to beindependently confirmed.

Detailed Description of Drugs

VEGF inhibitors or anti-VEGF therapy may involve binding of an agent toVEGF to prevent its modulation of a receptor such as VEGFR-1 (flt-1),VEGFR-2 (flk-1 or KDR), or through inhibition of tyrosine kinase inpromoting angiogenesis or it may inhibit the binding of VEGF to one ormore of its receptors by any one or more mechanisms. Regardless of themechanism of action, anti-VEGF activity associated with the use of aneffective amount of a VEGF inhibitor in the present invention results ina reduction in VEGF activity (angiogenesis/vascularization) in thetumor, and a response which is inhibitory to cancer growth, elaborationand metastases and which helps to promote cancer remission incombination with the other agents. Bevacizumab is a preferred VEGFinhibitor for use in the present invention. Compounds/compositionsaccording to the present invention which represent anti-VEGF therapy(angiogenesis inhibitors) include for example, ZD6474, ZD 6126, AZD2171(Astra Zeneca), SU6668 and SU5416 (Sugen), bevacizumab (Avastatin),mv833, anti-FLT-1 ribozyme (Angiozyme), and the tyrosine kinaseinhibitors SU5416 (Semaxanib), PTK 787 (ZK 222584), ZD4190, ZD6474,CEP-7055, SU11248 and mixtures thereof. In one embodimentanti-angiogenic agents include tumor-vascular disrupting agentsdescribed by Siemann (2011) [181], incorporated herein by reference.

Vandetanib (rINN, trade name Caprelsa), also known as ZD6474, is anantagonist of the vascular endothelial growth factor receptor (VEGFR)and the epidermal growth factor receptor (EGFR). It is a tyrosine kinaseinhibitor, being developed by AstraZeneca.

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol,related to colchicine.

Cediranib (tentative trade name Recentin), also known as AZD2171, is apotent inhibitor of vascular endothelial growth factor (VEGF) receptortyrosine kinases developed by Astra Zeneca.

SU6668, a multitargeted angiogenesis inhibitor described in Klenke, F.et al. (2007) [188], incorporated herein by reference.

Semaxanib (SU5416) is a tyrosine-kinase inhibitor drug designed by SUGENas a cancer therapeutic. It is an experimental stage drug, not licensedfor use on human patients outside of clinical trials. Semaxanib is apotent and selective synthetic inhibitor of the Flk-1/KDR vascularendothelial growth factor (VEGF) receptor tyrosine kinase. It targetsthe VEGF pathway, and both in vivo and in vitro studies havedemonstrated antiangiogenic potential.

Mv833 is anti-human VEGF monoclonal antibody.

Anti-FLT-1 ribozyme or Angiozyme is a substance that is being studied inthe treatment of kidney cancer. It may prevent the growth of bloodvessels from surrounding tissue to the tumor. It belongs to the familiesof drugs called VEGF receptor and angiogenesis inhibitors. Angiozyme isalso called RPI.4610.

The tyrosine kinase inhibitors include, but are not limited to: SU5416(Semaxanib), PTK 787 (Vatalanib), ZD4190, ZD6474 (Vandetanib), CEP-7055,and SU11248 (Sunitinib).

Semaxanib (SU5416) is a tyrosine-kinase inhibitor drug designed by SUGENas a cancer therapeutic. Semaxanib is a potent and selective syntheticinhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF)receptor tyrosine kinase. It targets the VEGF pathway, and both in vivoand in vitro studies have demonstrated antiangiogenic potential.

Vatalanib (also known as PTK787 or PTK/ZK) is a small molecule proteinkinase inhibitor that inhibits angiogenesis. Vatalanib is beingdeveloped by Bayer Schering and Novartis. It inhibits all known VEGFreceptors, as well as platelet-derived growth factor receptor-beta andc-kit, but is most selective for VEGFR-2.

Vandetanib (trade name Caprelsa), also known as ZD6474, is an antagonistof the vascular endothelial growth factor receptor (VEGFR) and theepidermal growth factor receptor (EGFR). It is a tyrosine kinaseinhibitor, being developed by AstraZeneca.

Sunitinib (marketed as Sutent by Pfizer, and previously known asSU11248) is an oral, small-molecule, multi-targeted receptor tyrosinekinase (RTK) inhibitor.

Bevacizumab (Avastin®) (rhuMAb-VEGFX Anti-VEGF monoclonal antibody) is arecombinant human/murine chimeric monoclonal antibody directed againstvascular endothelial growth factor (VEGF).). It is prepared byengineering VEGF-binding residues of a murine anti-VEGF monoclonalantibody into framework regions of human immunoglobulin-1 (IgG1) (ProdInfo Avastin, 2004). Only 7% of the amino acid sequence is derived fromthe murine antibody, with 93% from IgG1, Figg, W. D. et al. (2002) [189]incorporated herein by reference.

Human VEGF mediates neoangiogenesis in normal and malignant vasculature;it is overexpressed in most malignancies and high levels have correlatedwith a greater risk of metastases and poor prognosis in many. When VEGFinteracts with its receptor in in vitro models of angiogenesis,endothelial cell proliferation and new blood vessel formation occur. Inanimal models, VEGF has been demonstrated to induce vascularendothelial-cell proliferation/migration, sustain survival ofnewly-formed blood vessels, and enhance vascular permeability.Bevacizumab binds and neutralizes all human VEGF forms via recognitionof binding sites for the two human VEGF receptor types (flt-1 andflk-1). In animal models, the antibody has been shown to stabilizeestablished tumors or suppress tumor growth by inhibiting angiogenesisinduced by VEGF, Gordon, M. S. et al. (2001) [190] incorporated hereinby reference.

Toxicology of Bevacizumab: Minor bleeding or hemorrhage (eg, epistaxis,and hemoptysis), and thromboembolic events (eg, deep vein thrombosis)have accompanied administration of bevacizumab in some cancer patients.Other serious but uncommon events included; gastrointestinal hemorrhage,subarachnoid hemorrhage, fatal pulmonary hemorrhage, and hemorrhagicstroke (Prod Info Avastin™, 2004). Grade ¾ hypertension (12%), deepvenous thrombosis (9%), and intra-abdominal thrombosis (3%) occurred inpatients receiving bolus irinotecan/5-fluorouracil/leucovorin plusbevacizumab in a trial of patients with untreated metastatic colorectalcancer. Myocardial infarction and hypotension have also been reported.Modest increases in diastolic and systolic blood pressures and clinicalhypertension have been reported frequently during bevacizumab therapy(23% to 34% of patients) and may need to be controlled withantihypertensive medications. Mild asthenia and headache have beencommon during therapy (up to 70% and 50% of patients, respectively), butmay be dose-dependent. Dizziness (22%), hypokalemia (14%) andbilirubinemia (4%) vomiting (50%), anorexia (40%), constipation (30%),stomatitis (30%), dyspepsia (20%), weight loss (15%), taste disorder(16%) and flatulence (16%), myalgia (10%), skin ulcer (6%) and confusion(3%) may occur. Grade ¾ diarrhea (30%) and abdominal pain (6%) were alsoreported. Nausea and vomiting may be more severe with higher doses.Gastrointestinal perforation occurred in 2% of patients receiving bolusirinotecan/5-fluorouracil/leucovorin plus bevacizumab versus 4% ofpatients receiving 5-fluorouracil/leucovorin plus bevacizumab in a trialof patients with untreated metastatic colorectal cancer, a typicalpresentation included abdominal pain, constipation, and vomiting,Hurwitz, H. (2003)[191], incorporated herein by reference.

Proteinuria of varying severity or nephrotic syndrome has been describedduring therapy with bevacizumab, Cobleigh, M. A. et al. (2003) [192]incorporated herein by reference. Life threatening or fatal pulmonaryhemorrhage occurred in 3 to 1% of patients with squamous cell non-smallcell lung cancer (4% nonsquamous cell histology) receiving bevacizumabin combination with chemotherapy compared to 0% in the chemotherapyalone group; these events presented suddenly as major hemoptysis andoccurred in patients with cavitation and/or necrosis of the tumor,either preexisting or developing during therapy, Chen, et al. (2001)[193] incorporated herein by reference. Skin rash (type unspecified) hasbeen described in some patients following infusion. Low-grade fever andinfection have occurred with variable frequency during therapy. Theincidence of immunogenicity with bevacizumab exists, but has not beendetermined (prod info Avastin™, 2004). No antibodies to bevacizumab werereported in a phase I study (n=25) where patients received four doses of0.1 to 10 mg/kg over 42 days, and assays were performed for up to 70days, Gordon, M. S. et al. (2001) [190] incorporated herein byreference. There is insufficient clinical experience with bevacizumab toconfirm its safety in pregnancy.

Black Box Warnings for Bevacizumab: Gastrointestinal Perforations/WoundHealing Complications: Avastin administration can result in thedevelopment of gastrointestinal perforation and wound dehiscence, insome instances resulting in fatality. Gastrointestinal perforation,sometimes associated with intra-abdominal abscess, occurred throughouttreatment with Avastin (ie, was not correlated to duration of exposure).The incidence of gastrointestinal perforation in patients receivingbolus-IFL with Avastin was 2%. The typical presentation was reported asabdominal pain associated with symptoms such as constipation andvomiting. Gastrointestinal perforation should be included in thedifferential diagnosis of patients presenting with abdominal pain onAvastin. Avastintherapy should be permanently discontinued in patientswith gastrointestinal perforation or wound dehiscence requiring medicalintervention. The appropriate interval between termination of Avastinand subsequent elective surgery required to avoid the risks of impairedwound healing/wound dehiscence has not been determined.

Hemorrhage: Serious, and in some cases fatal, hemoptysis has occurred inpatients with non-small cell lung cancer treated with chemotherapy andAvastin. In a small study, the incidence of serious or fatal hemoptysiswas 31% in patients with squamous histology and 4% in patients withadenocarcinoma receiving Avastin as compared to no cases in patientstreated with chemotherapy alone. Patients with recent hemoptysis shouldnot receive Avastin.

Pharmacology of Bevacizumab: The pharmacokinetics of bevacizumab arelinear after doses of 0.3 mg/kg or greater. Following 90-minuteintravenous infusions of 0.3, 1, 3, and 10 mg/kg in advanced cancerpatients (n=25), peak serum concentrations of bevacizumab ranged from 5to 9 mcg/mL, 21 to 39 mcg/mL, 52 to 92 mcg/mL, and 186 to 294 mcg/mL,respectively; slight accumulation was observed with repeat doses(weekly), but this was not significant and pharmacokinetics remainedlinear. Steady-state levels of bevacizumab were obtained in 100 days in491 patients who received 1 to 20 mg/kg weekly, every 2 weeks, or every3 week Following 90-minute intravenous infusions of 0.3, 1, 3, and 10mg/kg in advanced cancer patients (n=25), AUC_(inf) values ranged from31 to 87, 240 to 382, 550 to 1720, and 2480 to 6010 mcg/mL×day,respectively, Gordon, M. S. et al. (2001) [190] incorporated herein byreference. Central volume of distribution of bevacizumab was greater inmales than in females (3.25 L vs. 2.66 L) in 491 patients who received 1to 20 mg/kg weekly, every 2 weeks, or every 3 week. The clearance ofbevacizumab was higher (0.262 L/day vs. 0.207 L/day) in males thanfemales; patients with a higher tumor burden (at or above median valueof tumor surface area) also had a higher clearance (0.249 L/day vs.0.199 L/day). The estimated elimination half-life of bevacizumab was 20days (range 11 to 50 days) in a pharmacokinetic population analysis of491 patients receiving 1 to 20 mg/kg weekly, every 2 weeks, or every 3weeks.

VEGF Serum Level Changes: In advanced cancer patients, free VEGF serumlevels were reduced significantly following the first dose ofbevacizumab 1 to 10 mg/kg, and remained below the limit of detection forthe duration of the study (repeat doses at 28, 35, and 42 days). Levelsof total VEGF increased with all doses (0.1 to 10 mg/kg), presumably asa result of increased VEGF synthesis/distribution or reduced VEGFclearance secondary to complex formation (between VEGF and bevacizumab),Gordon, M. S. et al. (2001) [190] herein incorporated by reference.

Storage And Stability: Store bevacizumab vials protected from light,under refrigeration at 2 to 8 degrees Celsius/36 to 46 degreesFahrenheit. Do not freeze or shake. This product contains nopreservative (Prod Info Avastin™, 2004).

Diluted solutions of bevacizumab in 100 mL 0.9% Sodium chlorideInjection may be stored for up to 8 hours under refrigeration (2 to 8degrees Celcius/36 to 46 degrees Fahrenheit) (Prod Info Avastin™, 2004).Early phase I trials were conducted with bevacizumab diluted in 5%Dextrose for Injection. However, results indicate that dextroseinactivates bevacizumab.

Dosage and Administration: The recommended dose of bevacizumab is 5milligrams/kilogram infused intravenously over 30 minutes every 2 weeksuntil disease progression diminishes. Bevacizumab should followchemotherapy. Efficacy of single-agent bevacizumab has not beenestablished. The calculated dose of bevacizumab in 100 milliliters of0.9% Sodium Chloride Injection should initially be infused over 90minutes; subsequent doses can be administered in shorter periods of time(60 minutes for the second infusion and 30 minutes for the thirdinfusion, if well-tolerated). Do not administer as an intravenous bolusor push (Prod Info Avastin™, 2004).

The term “effective” or “effective amount” means an amount of a compoundwhich is used to effect an intended result. In the present application,the favorable treatment of cancer is the intended effect, manifest in aremission or shrinkage of the cancer/tumor and/or the prevention or areduction in or the likelihood of the spread (metastases) of the cancerand a substantial increase in the time of survival. The present methodwill result in an increase in survival of a patient diagnosed withcancer to at least about 1.5 times, at least about 2 times, at leastabout 2.5 times, at least about 3 times, at least about 3.5 times, atleast about 4 times, at least about 5 times, at least about 6 times, atleast about 7 times, at least about 8 times, at least about 9 times andat least about 10 times or more the length of time of survival of theuntreated patient determined from the time the cancer is diagnosed inthe patient. Optimally, the present invention will result in theimprovement of the well being of the patient, a shrinkage of the tumor,a prolongation of survival, the remission of cancer and the prevention(as a manifestation of a reduced likelihood or prevention) of metastasesof the cancer to other areas of the patient's body. In general,effective amounts of each of the compounds used in the combined therapyaccording to the present invention include:

Bumetanide—between about 100 mg and 2.5 grams, preferably about 500 mgto about 2000 mg, preferably about 800 mg, about 1000 mg or about 1500mg/mm². A slow release form of bumetanide is preferably used such thatrelease of the drug would be evenly released over 8 to 12 hours. Inanother embodiment, the bumetanide is incorporated into polymers formuch longer term release.

Bevacizumab (which may be coadministered with bumetanide, or within aweek before or after chemotherapy), is administered intravenously, atabout 1 mg/kg to about 15 mg/kg, preferably about 5 mg/kg.

The above combination is preferably administered once about everyone-two weeks (preferably about every two weeks twice with eachcourse-one course equals 2 dosages—(preferably a total of 6 courses)preferably being administered over a 4-8 week period (preferably over 4weeks), although the regimen may be administered more frequentlydepending upon the disease state. Of course, further courses of thecombination therapy may be given, as the disease state merits. Thedosage of each of the components may be modified to reflect the size andweight of the patient, as well as the severity of the disease state tobe treated.

In some aspects of the present invention, the combined therapy describedabove is administered once every two weeks for a total of 12 dosages.The components are preferably co-administered, although it is sometimesdesirable to administer the bevacizumab (anti-VEGF therapy) within oneweek of the chermotheraputic compounds or compositions and/or a carbonicanhydrase inhibitor, such as bumetanide.

In additional aspects of the present invention, the premedicationsdexamethasone, at about 5-10 (preferably 8 mg) mg every 12 hours for sixdoses (three days) and/or zofran (5-10 mg, preferably 8 mg IV) areadministered in effective amounts prior to chemotherapy and thenintermittently during further therapy pursuant to physician discretion.The dosage schedules according the present invention are referred toherein as low dose, frequent administration.

Formulations

A“pharmaceutically acceptable monosaccharide” is a pharmaceuticallyacceptable aldose sugar, a pharmaceutically acceptable ketose sugar, orother specified sugar. Among the pharmaceutically acceptable aldosesugars within the contemplation of the present invention are erythrose,threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose,mannose, gulose, idose, galactose and talose. Among the pharmaceuticallyacceptable ketose sugars preferred for use in the composition of thepresent invention are erythrulose, ribulose, xylulose, psicose,fructose, sorbose, tagatose, and sedoheptulose. Among the otherspecified sugars preferred for use in the composition of the presentinvention are fucose, fuculose, rhamnose, or any other deoxy sugar.Although either (D) or (L) isomers may be employed, the (D) form isgenerally preferable.

The pharmaceutical compositions of the present invention may be preparedby formulating them in dosage forms which are suitable for peroral,rectal or nonparenteral administration, the last-mentioned includingintravenous injection and administration into the cerebrospinal fluid.For this purpose, common carriers and routine formulation techniques maybe employed.

“APT” or “active pharmaceutical ingredient” means the substance in apharmaceutical drug that is biologically active.

“Common carriers” means those which are employed in standardpharmaceutical preparations and includes excipients, binders anddisintegrators the choice of which depends on the specific dosage formused. Typical examples of the excipient are starch, lactose, sucrose,glucose, mannitol and cellulose; illustrative binders arepolyvinylpyrrolidone, starch, sucrose, hydroxypropyl cellulose and gumarabic; illustrative disintegrators include starch, agar, gelatinpowder, cellulose, and CMC. Any other common excipients, binders anddisintegrators may also be employed.

In addition, of the carriers described above, the pharmaceuticalcomposition of the present invention preferably contains antioxidantsfor the purpose of stabilizing the effective ingredient. Appropriateantioxidants may be selected from among those which are commonlyincorporated in pharmaceuticals and include ascorbic acid,N-acetylcysteine, acetylcysteine, L-cystein, D, L-α-tocopherol, andnatural tocopherol.

Formulations of the pharmaceutical composition of the present inventionwhich are suitable for peroral administration may be provided in theform of tablets, capsules, powders, granules, or suspensions innon-aqueous solutions such as syrups, emulsions or drafts, eachcontaining one or more of the active compounds in predetermined amounts.

The granule may be provided by first preparing an intimate mixture ofone or more of the active ingredients with one or more of the auxiliarycomponents shown above, then granulating the mixture, and classifyingthe granules by screening through a sieve.

The tablet may be prepared by compressing or otherwise forming one ormore of the active ingredients, optionally with one or more auxiliarycomponents.

The capsule may be prepared by first making a powder or granules as anintimate mixture of one or more of the active ingredients with one ormore auxiliary components, then charging the mixture into an appropriatecapsule on a packing machine, etc.

The pharmaceutical composition of the present invention may beformulated as a suppository (for rectal administration) with the aid ofa common carrier such a cocoa butter. The pharmaceutical composition ofthe present invention may also be formulated in a dosage form suitablefor non-parenteral administration by packaging one or more activeingredients as dry solids in a sterile nitrogen-purged container. Theresulting dry formulation may be administered to patientsnon-parenterally after being dispersed or dissolved in a given amount ofaseptic water.

The dosage forms are preferably prepared from a mixture of the activeingredients, routine auxiliary components and one or more of theantioxidants listed above. If desired, the formulations may furthercontain one or more auxiliary components selected from among excipients,buffers, flavoring agents, binders, surfactants, thickening agents, andlubricants.

The dose of the various pro-drugs will of course vary with the route ofadministration, the severity of the disease to be treated, and thepatient to be treated, but the exact dose ultimately chosen should beleft to the good discretion of the doctor responsible for the treatment.If a desired dose is determined, the active ingredient may beadministered once a day or, alternatively, it may be administered in upto as many portions as deemed appropriate at suitable intervals. Theactive ingredient may be straightforwardly administered without beingmixed with any other components. However, for several reasons, typicallyfor the purpose of providing ease in controlling the dose level, theactive compound is preferably administered in a pharmaceutical dosageform.

EXPERIMENTAL

Initial laboratory studies will be performed to determine if inhibitingor impairing the cancerous waste enzymes (CAIX,CAXII) can improve twotypes of treatment for cancer, arterial closure by embolization andNanoknife (cancer electroporation).

-   -   1. Glioblastoma rat model consisting of tumor implants in rat        brain. Protocol will likely include four groups: 1. control, 2.        GBM Rx'd with anti-VEGF, 3. GBM Rx'd with anti-VEGF and        Bumex, 4. GBM Rx'd with anti-VEGF, Bumex and monocarboxylic        transport inhibitor, such as pleuronic polymer 85 (other MCT)    -   2. Hepatoma rat model: implanted rat tumor in liver will be Rx'd        with 4 groups: 1. control, 2. occlusion of arterial flow, 3.        occlusion of arterial flow and Bumex, 4. anti-VEGF and Bumex        (anti-VEGF to include Avastin and other agents with multiple        targets, i.e. Sorafenib)

REFERENCES

-   1. Stahl, P. H. and Wermuth, C. G, (Eds.) (2002) Handbook of    Pharmaceutical Salts: Properties Selection and Use, Verlag Helvetica    Chimica Acta/Wiley-VCH, Zurich.-   2. Elger, G A. et al. “Controlled release pharmaceutical    composition,” U.S. Pat. No. 4,828,836 application Ser. No.    07/052,580, filed May 19, 1987. (Published May 9, 1989).-   3. Van Lengerich, B. H. “Embedding and encapsulation of controlled    release particles,” U.S. Pat. No. 6,190,591 application Ser. No.    09/269,763, filed May 17, 1999. (Published Feb. 20, 2001).-   4. Gimbrone, M. A. et al. (1972) Tumor Dormancy in Vivo by    Prevention of Neovascularization, The Journal of Experimental    Medicine 136(2), 261-276.-   5. Folkman, J. (1990) What Is the Evidence That Tumors Are    Angiogenesis Dependent?, J. Natl. Cancer Inst. 82(1), 4-7.-   6. Sheikh, A. Y. et al. (2000) Effect of hyperoxia on vascular    endothelial growth factor levels in a wound model, Arch. Surg.    135(11), 1293-1297.-   7. Stein, R. (2011) FDA revokes Avastin's approval for breast cancer    treatment, Washington Post, Washington, D.C. (Nov. 18, 2011).-   8. Jain, R. K. et al. (2006) Lessons from phase III clinical trials    on anti-VEGF therapy for cancer, Nature Clinical Practice Oncology    3(1), 24-40.-   9. Vaupel, P. (2004) The Role of Hypoxia-Induced Factors in Tumor    Progression, The Oncologist 9(suppl 5), 10-17.-   10. Keunen, O. et al. (2011) Anti-VEGF treatment reduces blood    supply and increases tumor cell invasion in glioblastoma, Proc.    Natl. Acad. Sci. U.S.A 108(9), 3749-3754.-   11. Nalluri, S. R. et al. (2008) Risk of Venous Thromboembolism With    the Angiogenesis Inhibitor Bevacizumab in Cancer Patients, JAMA: The    Journal of the American Medical Association 300(19), 2277-2285.-   12. Winkler, F. et al. (2004) Kinetics of vascular normalization by    VEGFR2 blockade governs brain tumor response to radiation: Role of    oxygenation, angiopoietin-1, and matrix metalloproteinases, Cancer    Cell 6(6), 553-563.-   13. Tong, R. T. et al. (2004) Vascular Normalization by Vascular    Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure    Gradient Across the Vasculature and Improves Drug Penetration in    Tumors, Cancer Res. 64(11), 3731-3736.-   14. Jain, R. K., Tong, R. T., and Munn, L. L. (2007) Effect of    Vascular Normalization by Antiangiogenic Therapy on Interstitial    Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights    from a Mathematical Model, Cancer Res. 67(6), 2729-2735.-   15. Jain, R. K. (2001) Normalizing tumor vasculature with    anti-angiogenic therapy: Anew paradigm for combination therapy, Nat.    Med. 7(9), 987-989.-   16. Workman, P. et al. (2006) Minimally invasive pharmacokinetic and    pharmacodynamic technologies in hypothesis-testing clinical trials    of innovative therapies, J. Natl. Cancer Inst. 98(9), 580-598.-   17. Miller, J. et al. (2005) Imaging angiogenesis: applications and    potential for drug development, J. Natl. Cancer Inst. 97(3),    172-187.-   18. Hu, L. S. et al. (2009) Relative Cerebral Blood Volume Values to    Differentiate High-Grade Glioma Recurrence from Posttreatment    Radiation Effect: Direct Correlation between Image-Guided Tissue    Histopathology and Localized Dynamic Susceptibility-Weighted    Contrast-Enhanced Perfusion MR Imaging Measurements, American    Journal of Neuroradiology 30(3), 552-558.-   19. Duong, T. Q. and Kim, S. G (2000) In vivo MR measurements of    regional arterial and venous blood volume fractions in intact rat    brain, Magn. Reson. Med 43(3), 393-402.-   20. Dvorak, H. et al. (2009) Distribution of Vascular Permeability    Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration    in Tumor Blood Vessels, The Journal of Experimental Medicine 174,    1275-1278.-   21. Dvorak, H. et al. (1988) Identification and characterization of    the blood vessels of solid tumors that are leaky to circulating    macromolecules, Am. J. Pathol. 133, 95-109.-   22. Nagy, J. A. et al. (2006) Permeability properties of tumor    surrogate blood vessels induced by VEGF-A, Lab. Invest. 86(8),    767-780.-   23. Nagy, J. A. et al. (2002) Vascular Permeability Factor/Vascular    Endothelial Growth Factor Induces Lymphangiogenesis as well as    Angiogenesis, The Journal of Experimental Medicine 196(11),    1497-1506.-   24. Kohn, S. et al. (1992) Pathways of macromaolecular tracer    transport across venules and small veins. Structural basis for the    hyperpermeability of tumor blood vessels, Lab. Invest. 67(5),    596-607.-   25. Kuhl, C. K. et al. (1999) Dynamic Breast MR Imaging: Are Signal    Intensity Time Course Data Useful for Differential Diagnosis of    Enhancing Lesions?, Radiology 211(1), 101-110.-   26. Kuhl, C. (2007) The Current Status of Breast MR Imaging Part I.    Choice of Technique, Image Interpretation, Diagnostic Accuracy, and    Transfer to Clinical Practice1, Radiology 244(2), 356-378.-   27. Kuhl, C. K. (2007) Current Status of Breast MR Imaging Part 2.    Clinical Applications1, Radiology 244(3), 672-691.-   28. Bisdas, S. et al. (2007) Differentiation of benign and malignant    parotid tumors using deconvolution-based perfusion CT imaging:    Feasibility of the method and initial results, Eur. J. Radiol.    64(2), 258-265.-   29. Caseiras, Q B. et al. (2008) Inclusion or Exclusion of    Intratumoral Vessels in Relative Cerebral Blood Volume    Characterization in Low-Grade Gliomas: Does It Make a Difference?,    American Journal of Neuroradiology 29(6), 1140-1141.-   30. Jain, R. et al. (2008) Quantitative estimation of permeability    surface-area product in astroglial brain tumors using perfusion CT    and correlation with histopathologic grade, AJNR, American journal    of neuroradiology 29(4), 694-700.-   31. Provenzale, J. M. et al, (2006) Correlation of Relative    Permeability and Relative Cerebral Blood Volumne in High-Grade    Cerebral Neoplasms, Am. J. Roentgenol. 187(4), 1036-1042.-   32. Spampinato, M. V. et al. (2007) Cerebral blood volume    measurements and proton MR spectroscopy in grading of    oligodendroglial tumors, AJR, American journal of roentgenology    188(1), 204-212.-   33. Hu, L. S. et al. (2009) Relative cerebral blood volume values to    differentiate high-grade glioma recurrence from posttreatment    radiation effect: direct correlation between image-guided tissue    histopathology and localized dynamic susceptibility-weighted    contrast-enhanced perfusion MR imaging measurements, AJNR, American    journal of neuroradiology 30(3), 552-558.-   34. Weidner, N. et al. (1991) Tumor Angiogenesis and    Metastasis—Correlation in Invasive Breast Carcinoma, N Engl. J. Med.    324(1), 1-8.-   35. Buckley, D. et al. (2005) Microvessel density in invasive breast    cancer assessed by dynamic gd-dtpa enhanced MRI, J. Magn. Reson.    Imaging 7(3), 461-464.-   36. Buadu, L. D. et al. (1996) Breast lesions: correlation of    contrast medium enhancement patterns on MR images with    histopathologic findings and tumor angiogenesis, Radiology 200(3),    639-649.-   37. Kriege, M. et al. (2004) Efficacy of MRI and Mammography for    Breast-Cancer Screening in Women with a Familial or Genetic    Predisposition, N. Engl. J. Med. 351(5), 427-437.-   38. El Khoury, C. et al (2005) MR Quantification of the Washout    Changes in Breast Tumors Under Preoperative Chemotherapy:    Feasibility and Preliminary Results, Am. J. Roentgenol. 184(5),    1499-1504.-   39. Radjenovic, A. et al. (2008) Measurement of pharmacokinetic    parameters in histologically graded invasive breast tumours using    dynamic contrast-enhanced MRI, Br. J Radiol. 81(962), 120-128.-   40. Raatschen, H.-J. et al. (2008) Vascular Permeability during    Antiangiogenesis Treatment: MR Imaging Assay Results as Biomarker    for Subsequent Tumor Growth in Rats1, Radiology 247(2), 391-399.-   41. Pham, C. et al. (1998) Magnetic resonance imaging detects    suppression of tumor vascular permeability after administration of    antibody to vascular endothelial growth factor, Cancer Investig.    16(4), 225-230.-   42. Thukral, A. et at (2007) Inflammatory Breast Cancer. Dynamic    Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial    Experience1, Radiology 244(3), 727-735.-   43. Boucher, Y., Lee, L, and Jain, R. K. (1995) Lack of General    Correlation between Interstitial Fluid Pressure and Oxygen Partial    Pressure in Solid Tumors, Micrvasc. Res. 50(2), 175-182.-   44. Boucher, Y. and Jain, I. K. (1992) Microvascular Pressure Is the    Principal Driving Force for Interstitial Hypertension in Solid    Tumors: Implications for Vascular Collapse, Cancer Res. 52(18),    5110-5114.-   45. Engelbrecht, M. R. et al. (2003) Discrimination of Prostate    Cancer from Normal Peripheral Zone and Central Gland Tissue by Using    Dynamic Contrast-enhanced MR Imaging Radiology 229(1), 248-254.-   46. Kim, J. K. et al. (2005) Wash-in rate on the basis of dynamic    contrast-enhanced MRI: Usefulness for prostate cancer detection and    localization, J. Magn. Reson. Imaging 22(5) 639-646.-   47. Jackson, a. S. N. et at (2009) Dynamic contrast-enhanced MRI for    prostate cancer localization, Br. J. Radiol. 82(974), 148-156.-   48. Franiel, T. et al. (2010) Differentiation of Prostate Cancer    From Normal Prostate Tissue: Role of Hotspots in Pharmacokinetic MRI    and Histologic Evaluation, Am. J. Roentgenol. 194(3), 675-681.-   49. Ito, H. et al. (2003) Visualization of prostate cancer using    dynamic contrast-enhanced MRI: comparison with transrectal power    Doppler ultrasound, Br J. Radiol. 76(909), 617-624.-   50. Ocak, I. et al. (2007) Dynamic Contrast-Enhanced MRI of Prostate    Cancer at 3 T: A Study of Pharmacokinetic Parameters, Am. J.    Roentgenol. 189, W192-W201.-   51. Schlemmer, H.-P. et al. (2004) Can pre-operative    contrast-enhanced dynamic MR imaging for prostate cancer predict    microvessel density in prostatectomy specimens?, Eur Radiol. 14(2),    309-317.-   52. Padhani, A. R. et al. (2000) Dynamic Contrast Enhanced MRI of    Prostate Cancer: Correlation with Morphology and Tumour Stage,    Histological Grade and PSA, Clin. Radiol. 55(2), 99-109.-   53. Jang, H.-J. et al. (2007) Enhancement Patterns of Hepatocellular    Carcinoma at Contrast-enhanced US: Comparison with Histologic    Differentiation, Radiology 244(3), 898-906.-   54. Jang, H.-J., Kim, T. K., and Wilson, S. R. (2006) Imaging of    Malignant Liver Masses: Characterization and Detection, Ultrasound    Quarterly 22(1), 19-29.-   55. Fan, Z.-H. et al. (2006) Evaluation of Primary Malignancies of    the Liver Using Contrast-Enhanced Sonography: Correlation With    Pathology, Am. J. Roentgenol. 186(6), 1512-1519.-   56. Liu, L. P. et al. (2009) Focal Hypoechoic Tumors of Fatty Liver.    Characterization of Conventional and Contrast-Enhanced    Lltrasonography, J. Ultrasound Med. 28, 1133-1142.-   57. Quaia, E. et al. (2007) Diagnostic Value of Hepatocellular    Nodule Vascularity After Microbubble Injection for Characterizing    Malignancy in Patients with Cirrhosis, Am J. Roentgenol. 189(6),    1474-1483.-   58. Frericks, B. et al. (2009) Qualitative and quantitative    evaluation of hepatocellular carcinoma and cirrhotic liver    enhancement using Gd-EOB-DTPA, AJR, American journal of    roentgenology 193(4), 1053-1060.-   59. Cheung, O. and Sanyal, A. J. (2010) Recent advances in    nonalcoholic fatty liver disease, Current Opinion in    Gastroenterology 26(3), 202-208.-   60. Goshima, S. et al. (2009) Optimal Acquisition Delay for Dynamic    Contrast-Enhanced MRI of Hypervascular Hepatocellular Carcinoma, Am    J Roentgenol. 192(3), 686-692.-   61. Ito, K. et al. (2004) Multiarterial Phase Dynamic MRI of Small    Early Enhancing Hepatic Lesions in Cirrhosis or Chronic Hepatitis:    Differentiating Between Hypervascular Hepatocellular Carcinomas and    Pseudolesions, Am. J. Roentgenol. 183(3), 699-705.-   62. Yoon, S. et al. (2009) Multiphasic MDCT enhancement pattern of    hepatocellular carcinoma smaller than 3 cm in diameter tumor size    and cellular differentiation, AJR, American journal of roentgenology    193(6), W482-489.-   63. Lee, K. H. Y. et al. (2004) Triple-Phase MDCT of Hepatocellular    Carcinoma, Am. J. Roentgenol. 182(3), 643-649.-   64. Fantin, V. R., St-Pierre, J., and Leder, P. (2006) Attenuation    of LDH-A expression uncovers a link between glycolysis,    mitochondrial physiology, and tumor maintenance, Cancer Cell 9(6),    425-434.-   65. Li, Y. M. et al. (2005) A Hypoxia-Independent Hypoxia-Inducible    Factor-1 Activation Pathway Induced by Phosphatidylinositol-3    Kinase/Akt in HER2 Overexpressing Cells, Cancer Res. 65(8),    3257-3263.-   66. Kim, J.-w. and Dang, C. V. (2006) Cancer's Molecular Sweet Tooth    and the Warburg Effect, Cancer Res. 66(18), 8927-8930.-   67. Pedersen, P. (2007) Warburg, me and Hexokinase 2: Multiple    discoveries of key molecular events underlying one of cancers' most    common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis    in the presence of oxygen, J. Bioenerg. Biomembr. 39(3), 211-222.-   68. Baumann, F. et al. (2009) Lactate promotes glioma migration by    TGF-beta2-dependent regulation of matrix metalloproteinase-2,    Neuro-oncol. 11(4), 368-380.-   69. Tang, W. and Hemler, M. E. (2004) Caveolin-1 Regulates Matrix    Metalloproteinases-1 Induction and CD147/EMMPRIN Cell Surface    Clustering, J. Biol. Chem. 279(12), 11112-11118.-   70. Le Floch, R. et al. (2011) CD147 subunit of lactate/H+    symporters MCT1 and hypoxia-inducible MCT4 is critical for    energetics and growth of glycolytic tumors, Proc. Natl. Acad. Sci.    U.S.A 108(40), 16663-16668.-   71. Brown, M. et al. (2008) NF-κB in carcinoma therapy and    prevention, Expert Opin. Ther Targets 12(9), 1109-1122.-   72. Shime, H. et al. (2008) Tumor-Secreted Lactic Acid Promotes    IL-23/IL-17 Proinflammatory Pathway, The Journal of Immunology    180(11), 7175-7183.-   73. Eskey, C. J. et al. (1993) Role of oxygen vs. glucose in energy    metabolism in a mammary carcinoma perfused ex vivo: direct    measurement by 31P NMR, Proc. Natl. Acad. Sci. U.S.A. 90(7),    2646-2650.-   74. Liu, Y. and Matsui, 0. (2007) Changes of Intratumoral    Microvessels and Blood Perfusion during Establishment of Hepatic    Metastases in Mice1, Radiology 243(2), 386-395.-   75. Manko f D. A. et al. (2002) Blood Flow and Metabolism in Locally    Advanced Breast Cancer: Relationship to Response to Therapy, J.    Nucl. Med 43(4), 500-509.-   76. Picchio, M. et al. (2008) Intratumoral Spatial Distribution of    Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD    Autoradiography, J. Nucl. Med 49(4) 597-605.-   77. Eby, P. R. et al. (2008) Metabolic and Vascular Features of    Dynamic Contrast-enhanced Breast Magnetic Resonance Imaging and    150-Water Positron Emission Tomography Blood Flow in Breast Cancer,    Acad. Radiol. 15(10), 1246-1254.-   78. Mayer, A. et al. (2005) Microregional Expression of Glucose    Transporter-1 and Oxygenation Status: Lack of Correlation in Locally    Advanced Cervical Cancers, Clinical Cancer Research 11(7),    2768-2773.-   79. Vaupel, P. and Thews, G (1976) Pathophysiological aspects of    glucose uptake by the tumor tissue under various conditions of    oxygen and glucose supply, Adv. Exp. Med. Biol. 75, 547-553.-   80. Gillies, R. and Gatenby, R. (2007) Adaptive landscapes and    emergent phenotypes: why do cancers have high glycolysis?, J.    Bioenerg. Biomembr. 39(3), 251-257.-   81. Gatenby, R. et al. (2006) Acid-mediated tumor invasion: a    multidisciplinary study, Cancer Res. 66(10), 5216-5223.-   82. Graeber, T. G et al. (1996) Hypoxia-mediated selection of cells    with diminished apoptotic potential in solid tumours, Nature    379(6560), 88-91.-   83. Semenza, Q L. et al. (1996) Hypoxia Response Elements in the    AldolaseA, Enolase 1, and Lactate Dehydrogenase A Gene Promoters    Contain Essential Binding Sites for Hypoxia-inducible Factor 1, J.    Biol. Chem. 271(51), 32529-32537.-   84. Walenta, S., Schroeder, T., and Mueller-Kliesser, W. (2004)    Lactate in solid malignant tumors: Potential basis of a metabolic    classification in clinical oncology, Curr Med. Chem. 11(16),    2195-2204.-   85. Hunt, T. et al. (2007) Aerobically derived lactate stimulates    revascularization and tissue repair via redox mechanisms, Antioxid    Redox. Signal. 9(8), 1115-1124.-   86. Assmann, V. et al. (1999) The intracellular hyaluronan receptor    RHAMM/IHABP interacts with microtubules and actin filaments, J. Cell    Sci. 112(22), 3943-3954.-   87. Hamilton, S. R. et al. (2007) The Hyaluronan Receptors CD44 and    Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal    Motility in Breast Cancer Cells, J. Biol. Chem. 282(22),    16667-16680.-   88. Gullino, P. M., Clark, S. H., and Grantham, F. H. (1964) The    Interstitial Fluid of Solid Tumors, Cancer Res. 24(5), 780-797.-   89. Lao, M.-S. and Toth, D. (1997) Effects of Ammonium and Lactate    on Growth and Metabolism of a Recombinant Chinese Hamster Ovary Cell    Culture, Biotechnol. Prog. 13(5), 688-691.-   90. Patel, S. D. et al. (2000) The Lactate Issue Revisited: Novel    Feeding Protocols To Examine Inhibition of Cell Proliferation and    Glucose Metabolism in Hematopoietic Cell Cultures, Biotechnol. Prog.    16(5), 885-892.-   91. Cruz, H. et al. (2000) Effects of ammonia and lactate on growth,    metabolism, and productivity of BHK cells, Enryme Microb. Technol.    27(1-2), 43-52.-   92. Ozturk, S. S., Riley, M. R., and Palsson, B. O. (1992) Effects    of ammonia and lactate on hybridoma growth, metabolism, and antibody    production, Biotechnol. Bioeng. 39(4), 418-431.-   93. Marx, E., Mueller-Klieser, W., and Vaupel, P. (1988)    Lactate-induced inhibition of tumor cell proliferation, Int. J.    Radiat. Oncol. Biol. Phys. 14(5), 947-955.-   94. Edkkili, K. et al. (2002) Lactate inhibits germ cell apoptosis    in the human testis, Mol. Hum. Reprod. 8(2), 109-117.-   95. Thangaraju, M. et al. (2006) SLC5A8 Triggers Tumor Cell    Apoptosis through Pyruvate-Dependent Inhibition of Histone    Deacetylases, Cancer Res. 66(24), 11560-11564.-   96. Samuvel, D. J. et al. (2009) Lactate Boosts TLR4 Signaling and    NF-κB Pathway-Mediated Gene Transcription in Macrophages via    Monocarboxylate Transporters and MD-2 Up-Regulation, The Journal of    Immunology 182(4), 2476-2484.-   97. Choi, E.-M. et al. (2005) COX-2 regulates p53 activity and    inhibits DNA damage-induced apoptosis, Biochem. Biophys. Res.    Commun. 328(4), 1107-1112.-   98. Brackstone, M., Townson, J. L., and Chambers, A. (2007) Tumour    dormancy in breast cancer an update, Breast Cancer Res. 9(3), 208.-   99. Rutz, H. P. and Little, J. B. (1995) Exogenous lactate    interferes with cell-cycle control in Balb 3T3 mouse fibroblasts,    Int. J. Radiat. Oncol. Biol. Phys. 31(3), 525-528.-   100. Hunt, T. K. et al. (2008) Lactate, with Oxygen, Incites    Angiogenesis, in Oxygen Thansport to Tissue XXIX (Kang, K. A.,    Harrison, D. K., and Bruley, D. F., Eds.), pp 73-80, Springer US.-   101. Dietl, K. et al. (2010) Lactic Acid and Acidification Inhibit    TNF Secretion and Glycolysis of Human Monocytes, The Journal of    Immunology 184(3), 1200-1209.-   102. Majewski, N. et al. (2004) Akt Inhibits Apoptosis Downstream of    BID Cleavage via a Glucose-Dependent Mechanism Involving    Mitochondrial Hexokinases, Mol. Cell. Biol. 24(2), 730-740.-   103. Kondoh, H. et al. (2005) Glycolytic Enzymes Can Modulate    Cellular Life Span, Cancer Res. 65(1), 177-185.-   104. Quennet, V. et al. (2006) Tumor lactate content predicts for    response to fractionated irradiation of human squamous cell    carcinomas in nude mice, Radiotherapy and oncology: Journal of the    European Society for Therapeutic Radiology and Oncology 81(2),    130-135.-   105. Sattler, U. G A. et al. (2010) Glycolytic metabolism and tumour    response to fractionated irradiation, Radiotherapy and oncology:    Journal of the European Society for Therapeutic Radiology and    Oncology 94(1), 102-109.-   106. Feldmeier, J. et al. (2003) Hyperbaric oxygen: does it promote    growth or recurrence of malignancy?, Undersea Hyper Med. 30(1),    1-18.-   107. Schbnmeyr, B. et al. (2008) The effect of hyperbaric oxygen    treatment on squamous cell cancer growth and tumor hypoxia, Ann.    Plast. Surg. 60(1), 81-88.-   108. Rutz, H. P. (1999) A biophysical basis of enhanced interstitial    fluid pressure in tumors, Med. Hypotheses 53(6), 526-529.-   109. Eichten, A., Hyun, W. C., and Coussens, L. M. (2007)    Distinctive Features of Angiogenesis and Lymphangiogenesis Determine    Their Functionality during De novo Tumor Development, Cancer Res.    67(11), 5211-5220.-   110. Hoshida, T. et al. (2006) Imaging Steps of Lymphatic Metastasis    Reveals That Vascular Endothelial Growth Factor-C Increases    Metastasis by Increasing Delivery of Cancer Cells to Lymph Nodes:    Therapeutic Implications, Cancer Res. 66(16), 8065-8075.-   111. Karpanen, T. et al. (2001) Vascular Endothelial Growth Factor C    Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth,    Cancer Res. 61(5), 1786-1790.-   112. Sonveaux, P. et al. (2008) Targeting lactate-fueled respiration    selectively kills hypoxic tumor cells in mice, J. Clin. Invest.    118(12), 3930-3942.-   113. Koukourakis, M.-I. et al (2006) Comparison of Metabolic    Pathways between Cancer Cells and Stromal Cells in Colorectal    Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma,    Cancer Res. 66(2), 632-637.-   114. Semenza, G L. (2008) Tumor metabolism: cancer cells give and    take lactate, J Clin. Invest. 118(12), 3835-3837.-   115. Heinzman, J. M., Brower, S. L., and Bush, J. E. (2008)    Comparison of angiogenesis-related factor expression in primary    tumor cultures under normal and hypoxic growth conditions, Cancer    Cell International 8, 11.-   116. Mukherjee, A. et al. (2005) Cytotoxic and antiangiogenic    activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in    vitro study, Br. J Cancer 92(2), 350-358.-   117. Mizukami, Y. et al. (2004) Hypoxia-Inducible    Factor-1-Independent Regulation of Vascular Endothelial Growth    Factor by Hypoxia in Colon Cancer, Cancer Res. 64(5), 1765-1772.-   118. Xiong, B. et al. (2002) TGF beta1 expression and angiogenesis    in colorectal cancer tissue, World J. Gastroenterol. 8(3), 496-498.-   119. Swift, M. R. and Weinstein, B. M. (2009) Arterial-Venous    Specification During Development, Circ. Res. 104(5), 576-588.-   120. Srinivasan, R. S. et al. (2007) Lineage tracing demonstrates    the venous origin of the mammalian lymphatic vasculature, Genes Dev.    21, 2422-2432.-   121. Höpfl, G, Ogunshola, O., and Gassmann, M. (2004) HIFs and    tumors—causes and consequences, American Journal of    Physiology—Regulatory, Integrative and Comparative Physiology    286(4), R608-R623.-   122. Lu, H. et al. (2005) Reversible Inactivation of HIF-1 Prolyl    Hydroxylases Allows Cell Metabolism to Control Basal HIF-1, J. Biol.    Chem. 280(51), 41928-41939.-   123. McFate, T.-et al. (2008) Pyruvate Dehydrogenase Complex    Activity Controls Metabolic and Malignant Phenotype in Cancer    Cells, J. Biol. Chem. 283(33), 22700-22708.-   124. Hägg M. and Wennström, S. (2005) Activation of hypoxia-induced    transcription in normoxia, Exp. Cell Res. 306(1), 180-191.-   125. Mekhail, K. et al. (2004) Oxygen Sensing by H+: Implications    for HIF and Hypoxic Cell Memory, Cell Cycle 3(8), 1025-1027.-   126. Chang, L. K. et al (2004) Dose-dependent response of FGF-2 for    lymphangiogenesis, Proc. Natl. Acad. Sci. U.S.A 101(32),    11658-11663.-   127. Pore, N. et al. (2004) Sp1 Is Involved in Akt-mediated    Induction of VEGF Expression through an HIF-1-independent Mechanism,    Mol. Biol. Cell 15(11), 4841-4853.-   128. Pore, N. et al. (2006) Akt1 Activation Can Augment    Hypoxia-Inducible Factor-1α Expression by Increasing Protein    Translation through a Mammalian Target of Rapamycin-Independent    Pathway, Mol. Cancer Res. 4(7), 471-479.-   129. Mizukami, Y. et al. (2006) Hypoxic Regulation of Vascular    Endothelial Growth Factor through the Induction of    Phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc, J. Biol. Chem.    281(20), 13957-13963.-   130. Stein, I. et al. (1995) Stabilization of vascular endothelial    growth factor mRNA by hypoxia and hypoglycemia and coregulation with    other ischemia-induced genes, Mol. Cell. Biol. 15(10), 5363-5368.-   131. Zhong, H. et al. (2000) Modulation of Hypoxia-inducible Factor    1α Expression by the Epidermal Growth Factor/Phosphatidylinositol    3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells:    Implications for Tumor Angiogenesis and Therapeutics, Cancer Res.    60(6), 1541-1545.-   132. Song, Y. et al. (2009) Sp-1 and c-Myc Mediate Lysophosphatidic    Acid-Induced Expression of Vascular Endothelial Growth Factor in    Ovarian Cancer Cells via a Hypoxia-Inducible Factor-1-Independent    Mechanism, Clinical Cancer Research 15(2), 492-501.-   133. D'Arcangelo, D. et al. (2000) Acidosis Inhibits Endothelial    Cell Apoptosis and Function and Induces Basic Fibroblast Growth    Factor and Vascular Endothelial Growth Factor Expression, Circ. Res.    86(3), 312-318.-   134. Fukumura, D. et al. (2001) Hypoxia and Acidosis Independently    Up-Regulate Vascular Endothelial Growth Factor Transcription in    Brain Tumors in Vivo, Cancer Res. 61(16), 6020-6024.-   135. Goerges, A. L. and Nugent, M. A. (2004) pH Regulates Vascular    Endothelial Growth Factor Binding to Fibronectin, J. Biol. Chem.    279(3), 2307-2315.-   136. Saksela, O. and Rifkin, D. B. (1990) Release of basic    fibroblast growth factor-heparan sulfate complexes from endothelial    cells by plasminogen activator-mediated proteolytic activity, The    Journal of Cell Biology 110(3), 767-775.-   137. Kato, Y. et al. (2005) Acidic Extracellular pH Induces Matrix    Metalloproteinase-9 Expression in Mouse Metastatic Melanoma Cells    through the Phospholipase D-Mitogen-activated Protein Kinase    Signaling, J. Biol. Chem. 280(12), 10938-10944.-   138. Shi, Q. et al. (2001) Regulation of vascular endothelial growth    factor expression by acidosis in human cancer cells, Oncogene    20(28), 3751-3756.-   139. Constant, J. S. et al. (2000) Lactate elicits vascular    endothelial growth factor from macrophages: a possible alternative    to hypoxia, Wound Repair. Regen. 8(5), 353-360.-   140. Beckert, S. et al. (2006) Lactate stimulates endothelial cell    migration, Wound Repair Regen. 14(3), 321-324.-   141. Jensen, J. A. et al. (1986) Effect of lactate, pyruvate, and pH    on secretion of angiogenesis and mitogenesis factors by macrophages,    Lab. Invest. 54(5), 574-578.-   142. Kumar, V. B. S. et al. (2007) Endothelial cell response to    lactate: Implication of PAR modification of VEGF, J Cell. Physiol.    211(2), 477-485.-   143. Xu, L., Fukumura, D., and Jain, R. K. (2002) Acidic    Extracellular pH Induces Vascular Endothelial Growth Factor (VEGF)    in Human Glioblastoma Cells via ERK1/2 MAPK Signaling Pathway, J.    Biol. Chem. 277(13), 11368-11374.-   144. Colotta, F. et al. (2009) Cancer-related inflammation, the    seventh hallmark of cancer: links to genetic instability,    Carcinogenesis 30(7), 1073-1081.-   145. Hong, Y.-K., Shin, J. W., and Detmar, M. (2004) Development of    the lymphatic vascular system: A mystery unravels, Dev. Dyn. 231(3),    462-473.-   146. Holash, J., Wiegand, S. J., and Yancopoulos, G D. (1999) New    model of tumor angiogenesis: dynamic balance between vessel    regression and growth mediated by angiopoietins and VEGF, Oncogene    18(38), 5356-5362.-   147. Moyon, D. et al. (2001) Plasticity of endothelial cells during    arterial-venous differentiation in the avian embryo, Development    128(17), 3359-3370.-   148. Hong, C. C. et al. (2006) Artery/Vein Specification Is Governed    by Opposing Phosphatidylinositol-3 Kinase and MAP Kinase/ERK    Signaling, Current biology: CB 16(13), 1366-1372.-   149. Indraccolo, S. et al. (2006) Interruption of tumor dormancy by    a transient angiogenic burst within the tumor microenvironment,    Proc. Natl. Acad. Sci. U.S.A 103(11), 4216-4221.-   150. Cao, Y. et al. (2005) Observation of Incipient Tumor    Angiogenesis That Is Independent of Hypoxia and Hypoxia Inducible    Factor-1 Activation, Cancer Res. 65(13), 5498-5505.-   151. Schmidt, D. et al. (2007) Critical role for NF-KB-induced JunB    in VEGF regulation and tumor angiogenesis, EMBO J. 26(3), 710-719.-   152. Hong, Y.-K. et al. (2004) VEGF-A promotes tissue    repair-associated lymphatic vessel formation via VEGFR-2 and the    α1β1 and α2β1 integrins, The FASEB Journal.-   153. Sato, Y. (2008) VEGFR1 for Lymphangiogenesis. An Alternative    Signaling Pathway?, Arterioscler. Thromb. Vasc. Biol. 28, 604.-   154. Kyzas, P. A., Stefanou, D., and Agnantis, N. J. (2004) COX-2    expression correlates with VEGF-C and lymph node metastases in    patients with head and neck squamous cell carcinoma, Mod. Pathol.    18(1), 153-160.-   155. Timoshenko, A. V. et al. (2006) COX-2-mediated stimulation of    the lymphangiogenic factor VEGF-C in human breast cancer, Br. J.    Cancer 94(8), 1154-1163.-   156. Enholm, B. et al. (2001) Adenoviral Expression of Vascular    Endothelial Growth Factor-C Induces Lymphangiogenesis in the Skin,    Circ. Res. 88(6), 623-629.-   157. Nagy, J. A. et al. (2002) VEGF-A induces angiogenesis,    arteriogencsis, lymphangiogenesis, and vascular malformations, Cold    Spring Harbor Symp. Quant. Biol. 67, 227-237.-   158. Pettersson, A. et al. (2000) Heterogeneity of the Angiogenic    Response Induced in Different Normal Adult Tissues by Vascular    Permeability Factor/Vascular Endothelial Growth Factor, Lab. Invest.    80(1), 99-115.-   159. Vihanto, M. M. et al. (2005) Hypoxia up-regulates expression of    Eph receptors and ephrins in mouse skin, The FASEB Journal.-   160. Huang, X. et al. (2007) EphB4 Overexpression in B16 Melanoma    Cells Affects Arterial-Venous Patterning in Tumor Angiogenesis,    Cancer Res. 67(20), 9800-9808.-   161. Hayashi, S.-i. et al. (2005) Functional Ephrin-B2 Expression    for Promotive Interaction Between Arterial and Venous Vessels in    Postnatal Neovascularization, Circulation 111(17), 2210-2218.-   162. Yancopoulos, G D. et al. (2000) Vascular-specific growth    factors and blood vessel formation, Nature 407(6801), 242-248.-   163. Patan, S. et al. (2001) Vascular Morphogenesis and Remodeling    in a Human Tumor Xenograft, Circ. Res. 89(8), 732-739.-   164. Li, C.-Y. et al. (2000) Initial Stages of Tumor Cell-Induced    Angiogenesis: Evaluation Via Skin Window Chambers in Rodent    Models, J. Natl. Cancer Inst. 92(2), 143-147.-   165. Koyama, H. et al. (2008) Significance of Tumor-Associated    Stroma in Promotion of Intratumoral Lymphangiogenesis: Pivotal Role    of a Hyaluronan-Rich Tumor Microenvironment, The American journal of    pathology 172(1), 179-193.-   166. Pasqui, D. et al. (2005) Hyaluronan and sulphated hyaluronan    micropatterns: effect of chemical topographic cues on lymphatic    endothelial cell alignment and proliferation, Lymphology 38(2),    50-65.-   167. Hendriksen, E. M. et al. (2009) Angiogenesis, hypoxia and VEGF    expression during tumour growth in a human xenograft tumour model,    Microvasc. Res. 77(2), 96-103.-   168. Itano, N. et al. (2002) Abnormal accumulation of hyaluronan    matrix diminishes contact inhibition of cell growth and promotes    cell migration, Proc. Natl. Acad. Sci. U.S.A 110. 99(6), 3609-3614.-   169. Koyama, H. et al. (2007) Hyperproduction of Hyaluronan in    Neu-Induced Mammary Tumor Accelerates Angiogenesis through Stromal    Cell Recruitment: Possible Involvement of Versican/PG-M, The    American journal of pathology 170(3), 1086-1099.-   170. Hall, C. L and Turley, E. A. (1995) Hyaluronan: RHAMM mediated    cell locomotion and signaling in tumorigenesis, J. Neurooncol.    26(3), 221-229.-   171. Fischer, K. et al. (2007) Inhibitory effect of tumor    cell-derived lactic acid on human T cells, Blood 109(9), 3812-3819.-   172. Kuang, D.-M. et al. (2007) Tumor-derived hyaluronan induces    formation of immunosuppressive macrophages through transient early    activation of monocytes, Blood 110(2), 587-595.-   173. Lin, E. Y. et al. (2006) Macrophages Regulate the Angiogenic    Switch in a Mouse Model of Breast Cancer, Cancer Res. 66(23),    11238-11246.-   174. Alphonso, A. and Alahari, S. K. (2009) Stromal cells and    integrins: Conforming to the needs of the tumor microenvironment,    Neoplasia 11(12), 1264-1271.-   175. Nissen, N. N. et al. (1999) Heparin and heparan sulphate    protect basic fibroblast growth factor from non-enzymic    glycosylation, Biochem. J. 338(3), 637-642.-   176. Arbiser, J. L. (2007) Why targeted therapy hasn't worked in    advanced cancer, J. Clin. Invest. 117(10), 2762-2765.-   177. Yoshiji, H., Harris, S. R., and Thorgeirsson, U. P. (1997)    Vascular Endothelial Growth Factor Is Essential for Initial but not    Continued in Vivo Growth of Human Breast Carcinoma Cells, Cancer    Res. 57(18), 3924-3928.-   178. Giavazzi, R. et al. (2001) Modulation of Tumor Angiogenesis by    Conditional Expression of Fibroblast Growth Factor-2 Affects Early    but not Established Tumors, Cancer Res. 61(2), 309-317.-   179. Grillon, E. et al. (2011) The spatial organization of proton    and lactate transport in a rat brain tumor, PLoS One 6(2), e17416.-   180. Selvakumaran, M. et al. (2008) Antitumor effect of the    angiogenesis inhibitor bevacizumab is dependent on susceptibility of    tumors to hypoxia-induced apoptosis, Biochem. Pharmacol. 75(3),    627-638.-   181. Siemann, D. W. (2011) The unique characteristics of tumor    vasculature and preclinical evidence for its selective disruption by    Tumor-Vascular Disrupting Agents, Cancer Treat. Rev. 37(1), 63-74.-   182. Davis, P. A. and Cousins, S. “Biodegradable injectable drug    delivery polymer,” U.S. Pat. No. 5,384,333, filed Mar. 17, 1992.    (Published Jan. 24, 1995).-   183. Amsden, B. G and Cheng, Y.-I. “Polymer-based drug delivery    system,” U.S. Pat. No. 5,302,397, filed Nov. 19, 1991. (Published    Apr. 12, 1994).-   184. Amsden, B. G and Cheng, Y.-I. “Polymer-based drug delivery    system,” U.S. Pat. No. 5,626,877, filed Feb. 9, 1994. (Published May    6, 1997).-   185. Wadee, A. et al. (2011) Recent advances in the design of    drug-loaded polymeric implants for the treatment of solid tumors,    Expert Opin. Drug Deliv. 8(10), 1323-1340.-   186. Hamed, E. A. M. (2002) Application and Evaluation of Extended    Release Technology to Loop Diuretics, in Department of    Pharmaceutical Sciences of the College of Pharmacy, p 208,    University of Cincinnati.-   187. Schoenwald, R. D. and Barflmecht, C. F. “Prodrugs of carbonic    anhydrase inhibitors,” U.S. Pat. No. 5,095,026 application Ser. No.    07/410,982, filed Sep. 22, 1989. (Published Mar. 10, 1992).-   188. Klenke, F. et al. (2007) Tyrosine kinase inhibitor SU6668    represses chondrosarcoma growth via antiangiogenesis in vivo, BMC    Cancer 7(1), 49.-   189. Figg, W. D. et al. (2002) Inhibition of Angiogenesis: Treatment    Options for Patients with Metastatic Prostate Cancer, Invest. New    Drugs 20(2), 183-194.-   190. Gordon, M. S. et al. (2001) Phase I Safety and Pharmnacokinetic    Study of Recombinant Human Anti-Vascular Endothelial Growth Factor    in Patients With Advanced Cancer, Journal of Clinical Oncology    19(3), 843-850.-   191. Hurwitz, H. (2003) Bevacizumab (Avastin, amonoclonal antibody    to vascular endothelial growth factor) prolongs survival in    first-line colorectal cancer (CRC): results of a phase III trial of    bevacizumab in combination with bolus IFL (irinotecan,    5-fluorouracil, leucovorin), in Presented at the 39th Annual    American Society of Clinical Oncology Meeting, Chicago, Ill.-   192. Cobleigh, M. A. et al. (2003) A phase I/II dose-escalation    trial of bevacizumab in previously treated metastatic breast cancer,    Semin. Oncol. 30, 117-124.-   193. Chen, H. X., Gore-Langton, R. E., and Cheson, B. D. (2001)    Clinical trials referral resource: Current clinical trials of the    anti-VEGF monoclonal antibody bevacizumab, Oncology (Williston Park)    15(8), 1017, 1020, 1023-1016.

1-36. (canceled)
 37. A method for treating a patient with cancer, saidmethod comprising: a) providing: i) a patient exhibiting a neoplasm,wherein said neoplasm comprises a plurality of blood vessels; and ii) acomposition comprising at least one polymer and bumetanide; b)administering said composition to said patient under conditions suchthat said blood vessels are occluded.
 38. The method according to claim37, wherein said neoplasm is hypoxic.
 39. The method according to claim37, wherein said administering results in the shrinkage of saidneoplasm.
 40. The method according to claim 37, wherein said bloodvessel occlusions comprise emboli.
 41. The method according to claim 37,wherein said emboli comprises said composition.
 42. The method accordingto claim 37, wherein said administering further comprises a thermalablation of said neoplasm.
 43. The method according to claim 42, whereinsaid thermal ablation is preceded by said bumetanide compositionadministration.
 44. The method according to claim 42, wherein saidthermal ablation comprises radiofrequency thermal ablation.
 45. Themethod according to claim 42, wherein said thermal ablation comprisescryoablation.
 46. The method according to claim 42, wherein said thermalablation comprises microwave ablation.
 47. The method according to claim42, wherein said thermal ablation comprises laser ablation.
 48. Themethod according to claim 42, wherein said thermal ablation comprisesultrasound ablation.
 49. The method according to claim 37, wherein saidadministering further comprises an angiogenesis inhibitor.
 50. Themethod according to claim 49, wherein said angiogenesis inhibitor isselected from the group consisting of ZD6474, ZD 6126, AZD2171, SU6668,SU5416, bevacizumab, mv833, anti-FLT-1 ribozyme, SU5416, PTK 787,ZD4190, ZD6474, CEP-7055, SU11248, and mixtures thereof.
 51. The methodaccording to claim 41, wherein said administering of said composition isrepeated.
 52. The method according to claim 41, wherein said compositioncomprises a slow-release polymer formulation.